MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
i
 
Protocol Title:
 
 
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the 
Treatment of Central Retinal Vein Occlusions
 
NCT 
Number: 
[STUDY_ID_REMOVED]
 
Date of This Submission/Version: 
September 1
9
, 2018
/
v
1
9
.0
 
Principal Investigator
 
Catherine Cukras, MD, 
PhD
 
NEI/NIH
 
Building 10
,
 
Room 10
C438
 
301
-
435
-
5061
 
cukrasc@nei.nih.gov
 
Principal Investigator
 
–
 
Biomedical Research Centre (BRC)
 
Sites
 
Clare Bailey, MD
 
BEH/
 
UHB
 
Bristol Eye 
Hospital
 
+44 (0) 7939
-
 
152
-
376
 
clare.bailey@bristol.ac.uk
 
Bishwanath Pal, 
MBBS, MS, Ophth,
 
FRCOphth, FRCSEdin
 
MEH
 
Moorfields 
Eye Hospital
 
+44 (0) 207
-
566
-
2419
 
Bishwanath.Pal@moorfiel
ds.nhs.uk
 
Lead Associate Investigator
 
Wai Wong, MD, PhD
 
NEI/NIH
 
Building 6
,
 
Room 217
 
301
-
496
-
7566
 
wongw@nei.nih.gov
 
Associate 
Investigators
 
Emily Y. Chew, MD
 
NEI/NIH
 
Building 10
,
 
Room 3
-
2531
 
301
-
496
-
6583
 
echew@nei.nih.gov
 
Henry Wiley, MD
 
NEI/NIH
 
Building 10
,
 
Room 10D45
 
301
-
451
-
4261
 
wileyhe@nei.nih.gov
 
Awilda V.
 
Holland, 
DNP, MSHSc, RN, 
CCRP
 
NIH/NEI
 
Building 10,
 
R
oo
m 10D45
 
301
-
435
-
1831
 
aholland@mail.nih.gov
 
Angela Kibiy, MPH, 
BSN, RN
 
NEI/NIH
 
Building 10
,
 
Room 10D45
 
301
-
435
-
1833
 
a
ngela.kibiy@nih.gov
 
Alexander Kaplan, MD
 
NIH/NEI
 
Building 10,
 
Room 10D45
 
301
-
443
-
8557
 
alex.kaplan@nih.gov
 
Munir Iqbal, MD, 
FRCSC
 
NIH/NEI
 
Building 10,
 
Room 3
-
2531
 
301
-
496
-
6583
 
munir.iqbal@nih.gov
 
Christopher Hwang, 
MD
 
NIH/NEI
 
Building 10,
 
Room 3
-
2531
 
301
-
496
-
6583
 
christopher.hwang@nih.gov
 
Medically Accountable Investigator
 
Emily Y. Chew, MD
 
NEI/NIH
 
Building 10
,
 
Room 3
-
2531
 
301
-
496
-
6583
 
echew@nei.nih.gov
 
Research Contact 
 
Angela Kibiy, MPH, 
BSN, RN
 
NEI/NIH
 
Building 10
,
 
Room 10D45
 
301
-
435
-
1833
 
a
ngela.kibiy@nih.gov
 
 
 
 
MiC
RVO
 
September 19, 2018
 
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
ii
 
Coordinating Center
 
:
 
The 
Emmes
 
Corporation
 
(Emmes)
 
401 North Washington St.
, 
Suite 700
 
Rockville, MD 20850 USA
 
Phone: (301) 251
-
1161
 
Facsimile: (202) 478
-
0243
 
 
Participating Site
:
 
 
Bristol Eye Hospital (BEH)
 
Lower Maudlin Street
 
Bristol BS1 2LX, UK
 
Phone: +4401173424613
 
Facsimile: +4401173424721
 
 
Moorfields Eye Hospital
 
(MEH)
 
The John 
Saunders Suite
 
9
-
11 Bath Street
 
London EC1V 9LF, UK
 
Phone: +44 (0) 2075
-
662
-
419
 
Fax: +44 (0) 207
5
-
662
-
972
 
 
Human Research Protections Program Investigator and Staff Training:
 
“Just in time” human subjects protection training courses are required for invest
igators and staff 
participating on this protocol: None
 
 
Total Requested Accrual:
 
20
 
Participants 
–
 
A minimum of 10 and a maximum of 
 
20 participants will be accrued.
 
0
 
Healthy Volunteers
 
 
Project Uses Ionizing Radiation:
 
 
 
No
 
 
Yes
 
 
IND/IDE:
 
 
No 
 
 
Yes
 
Drug/Device #:
 
108,154
 
Sponsor: 
 
Catherine Cukras, MD, PhD
 
 
EudraCT
:
 
 
 
 
 
 
No 
 
 
 
Yes
 
 
Drug/Device #:
 
2017
-
001143
-
12
 
 
Chief Investigator: 
 
Clare Bailey, MD
 
 
Durable Power of Attorney:
 
 
No 
 
 
Yes
 
 
Multi
-
institutional Project:
 
 
No 
 
 
Yes
 
 
 
MiC
RVO
 
September 19, 2018
 
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
iii
 
Site
 
FWA
 
Coordinating Center:
 
National Eye Institute (NEI)
 
FWA00005897
 
Participating Center:
 
Bristol Eye Hospital (BEH)
 
Principal Investigator: Clare Bailey, MD
 
FWA00000523
 
Participating Center:
 
Moorfields Eye Hospital (MEH)
 
Principal Investigator: 
Bishwanath Pal
,
 
MBBS, MS, Ophth,
 
FRCOphth, 
FRCSEdin
 
FWA00010199
 
 
Additional sites may be identified and added to this study in future amendments.
 
Data and Safety 
Monitoring Board
:
 
 
No 
 
 
Yes
 
 
Technology Transfer Agreement:
 
 
 
 
No 
 
 
 
Yes
 
 
Sampl
es Being Stored for Future Use:
 
 
 
No 
 
 
Yes
 
 
Flesch
-
Kincaid Reading Level of Consent Form:
 
 
9.5
 
MiC
RVO
 
September 19, 2018
 
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
iv
 
T
ABLE OF 
C
ONTENTS
 
P
ROTOCOL 
A
BBREVIATIONS 
L
IST
 
................................
................................
................................
 
VI
 
P
RÉCIS
 
................................
................................
................................
................................
............
 
1
 
1.0
 
I
NTRODUCTION
/S
CIENTIFIC 
R
ATIONALE
 
................................
................................
.............
 
3
 
1.1
 
Central Retinal Vein Occlusions
 
................................
................................
.....................
 
3
 
1.2
 
Current Treatments of CRVO
 
................................
................................
.........................
 
4
 
1.3
 
Role of Microglia
 
................................
................................
................................
............
 
4
 
1.4
 
Role of Microglia in Retinal Vein Occlusions
 
................................
................................
 
5
 
1.5
 
Minocycline as a Microglia Inhibitor
 
................................
................................
.............
 
6
 
1.5.1
 
Minocycline
 
................................
................................
................................
................
 
6
 
1.5.2
 
Precli
nical Studies with Minocycline
 
................................
................................
.........
 
7
 
1.5.3
 
Clinical Use and Clinical Studies with Minocycline
 
................................
..................
 
7
 
2.0
 
S
TUDY 
O
BJECTIVE
 
................................
................................
................................
.................
 
8
 
3.0
 
P
ARTICIPANTS
 
................................
................................
................................
.......................
 
8
 
3.1
 
Particip
ant Eligibility Criteria
 
................................
................................
.........................
 
8
 
3.1.1
 
Inclusion Criteria
 
................................
................................
................................
........
 
8
 
3.1.2
 
Exclusion Criteria
 
................................
................................
................................
.....
 
10
 
3.2
 
Study Eye Eligibility Criteria
................................
................................
........................
 
11
 
3.2.1
 
Study Eye Inclusion Criteria
 
................................
................................
.....................
 
11
 
3.2.2
 
Study Eye Exclusion Criteria
 
................................
................................
....................
 
12
 
3.2.3
 
Study Eye Selection Criteria in Cases of Bilateral Disease
 
................................
......
 
13
 
4.0
 
S
TUDY 
D
ESIGN AND 
M
ETHODS
 
................................
................................
...........................
 
13
 
4.1
 
Study Overview
 
................................
................................
................................
............
 
13
 
4.2
 
Recruitment
 
................................
................................
................................
...................
 
13
 
4.3
 
Screening
................................
................................
................................
.......................
 
14
 
4.4
 
Randomization, Masking and Unmasking
 
................................
................................
....
 
15
 
4.5
 
Study Design and Procedures
 
................................
................................
.......................
 
15
 
4.5.1
 
Treatment Prior to Month 3
 
................................
................................
......................
 
18
 
4.5.2
 
Treatment Beginning at Month 3
 
................................
................................
..............
 
18
 
4.6
 
Ocular and Systemic Evaluations
 
................................
................................
.................
 
21
 
4.6.1
 
Reporting of Expected Events
 
................................
................................
..................
 
22
 
4.7
 
Study and Concomitant Therapy
 
................................
................................
..................
 
23
 
4.7.1
 
Minocycline Formulation at Pine Pharmaceuticals
 
................................
..................
 
23
 
4.7.2
 
Minocycline Formulation for BRC Sites
 
................................
................................
..
 
23
 
4.7.3
 
Placebo Formulation at Pine Pharmaceuticals
 
................................
..........................
 
23
 
4.7.4
 
Placebo Formulation for BRC Sites
 
................................
................................
..........
 
24
 
4.7.5
 
Dosage, Administration and Storage
 
................................
................................
........
 
24
 
4.7.6
 
Concomitant Therapy
................................
................................
................................
 
24
 
4.8
 
Investigational Product Accountability
 
................................
................................
.........
 
24
 
4.9
 
Follow
-
up/Termination Procedures
 
................................
................................
..............
 
25
 
4.10
 
Storage of Samples and Data
 
................................
................................
........................
 
25
 
 
 
 
MiC
RVO
 
May 31, 2018
 
 
T
ABLE OF 
C
ONTENTS
 
(C
ONTINUED
)
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
v
 
5.0
 
R
ISKS
/D
ISCOMFORTS
 
................................
................................
................................
..........
 
25
 
5.1
 
Intravitreal Bevacizumab Risks
 
................................
................................
....................
 
27
 
5.2
 
Investigational Product Risks
 
................................
................................
.......................
 
27
 
5.2.1
 
Minocycline
-
related
 
................................
................................
................................
..
 
27
 
5.2.2
 
Drug Interaction
-
related
 
................................
................................
............................
 
29
 
5.2.3
 
Placebo
-
related
 
................................
................................
................................
..........
 
29
 
6.0
 
P
ARTICIPANT 
M
ONITORING
 
................................
................................
................................
 
29
 
6.
1
 
Individual Withdrawal Criteria
 
................................
................................
.....................
 
29
 
6.2
 
Pregnancy Monitoring
 
................................
................................
................................
..
 
30
 
7.0
 
O
UTCOME 
M
EASURES
 
................................
................................
................................
.........
 
31
 
7.1
 
Prim
ary Outcome
 
................................
................................
................................
..........
 
31
 
7.2
 
Secondary Outcomes
 
................................
................................
................................
....
 
31
 
7.3
 
Safety Outcomes
 
................................
................................
................................
...........
 
32
 
8.0
 
S
TAT
ISTICAL 
A
NALYSIS
 
................................
................................
................................
......
 
32
 
9.0
 
H
UMAN 
P
ARTICIPANTS 
P
ROTECTION
 
................................
................................
.................
 
34
 
9.1
 
Equitability
 
................................
................................
................................
....................
 
34
 
9.1.1
 
Justif
ication for Exclusion of Children
 
................................
................................
.....
 
34
 
9.1.2
 
Justification for Exclusion of Pregnant or Lactating Women
 
................................
...
 
35
 
9.2
 
Qualifications of Investigators
 
................................
................................
......................
 
35
 
9.2.1
 
Professional Licensure
 
................................
................................
..............................
 
37
 
10.0
 
A
NTICIPATED 
B
ENEFITS
 
................................
................................
................................
......
 
38
 
11.0
 
C
LASSIFICATION OF 
R
ISK
 
................................
................................
................................
...
 
38
 
12.0
 
C
ONSENT 
D
OCUMENTS AND 
P
ROCESS
 
................................
................................
................
 
38
 
12.1
 
Unanticipated Enrollment of Non
-
English Speaking Partic
ipants at the NEI
 
..............
 
39
 
13.0
 
D
ATA AND 
S
AFETY 
M
ONITORING
 
................................
................................
.......................
 
39
 
13.1
 
Coordinating Center
 
................................
................................
................................
......
 
40
 
13.2
 
Data and Safety Monitoring Committee
 
................................
................................
.......
 
40
 
13.3
 
Criteria for Stopping the Study
 
................................
................................
.....................
 
41
 
14.0
 
Q
UALITY 
A
SSURANCE
 
................................
................................
................................
.........
 
41
 
15.0
 
R
EPORTING OF 
U
NANTICIPATED 
P
ROBLEMS
,
 
A
DVERSE 
E
VENTS AND 
P
ROTOCOL 
D
EVIATIONS
 
................................
................................
................................
................................
..
 
42
 
16.0
 
A
LTERNATIVE 
T
HERAPIES
 
................................
................................
................................
..
 
43
 
17.0
 
P
RIVACY
 
................................
................................
................................
..............................
 
43
 
18.0
 
C
ONFIDENTIALITY
 
................................
................................
................................
...............
 
43
 
19.0
 
C
ONFLICT OF 
I
NTEREST
 
................................
................................
................................
......
 
44
 
20.0
 
T
ECHNOLOGY 
T
RANSFER
................................
................................
................................
....
 
44
 
21.0
 
R
ESEARCH AND 
T
RAVEL 
C
OMPENSATION
................................
................................
..........
 
44
 
22.0
 
R
EFERENCES
 
................................
................................
................................
........................
 
45
 
A
PPENDIX 
1:
 
D
ETERMINING 
C
HILDBEARING 
P
OTENTI
AL
 
................................
..........................
 
49
 
A
PPENDIX 
2:
 
S
TUDY 
F
LOWSHEET
 
................................
................................
................................
 
50
 
A
PPENDIX 
3:
 
L
IST OF 
D
EFINITIONS
 
................................
................................
.............................
 
52
 
MiC
RVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
vi
 
P
ROTOCOL 
A
BBREVIATIONS 
L
IST
 
AE
 
Adverse Event
 
ALS
 
Amyotrophic Lateral Sclerosis
 
APD
 
Afferent Pupillary Defect
 
BCVA
 
Best 
Corrected Visual Acuity
 
BEH
 
Bristol Eye Hospital
 
BRB
 
Blood
-
Retinal Barrier
 
BRC
 
Biomedical Research Centre
 
BRVO
 
Branch Retinal Vein Occlusion
 
BUN
 
Blood Urea Nitrogen
 
CBC
 
Complete Blood Count
 
CC
 
Clinical Center
 
CD
 
Clinical Director
 
CD
-
68
 
Clusters of Differentiation 68
 
CFP
 
Color Fundus Photography
 
CFR
 
Code of Federal Regulation
 
CNS
 
Central Nervous System
 
CNS IRB
 
Combined NeuroScience Institutional Review Board
 
COX
-
2
 
Cyclooxygenase
-
2
 
CRIS
 
Clinical Research Information System
 
CTCAE
 
Common Terminology Criteria for Adverse Events
 
CVA
 
Cerebral Vascular Event
 
DME
 
Diabetic Macular Edema
 
DSMC
 
Data and Safety Monitoring Committee
 
Emmes
 
The Emmes Corporation
 
EMR
 
Electronic Medical Record
 
ETDRS
 
Early Treatment Diabetic 
Retinopathy Study
 
EudraCT
 
European Clinical Trials Database
 
FA
 
Fluorescein Angiogram
 
FDA
 
Food and Drug Administration
 
FGF
 
Fibroblast Growth Factor
 
FSH
 
Follicle
-
Stimulating Hormone
 
HRPP
 
Human Research Protections Program
 
HRVO
 
Hemi
-
Retinal Vein 
Occlusion
 
ICE
 
IL
-
1b
-
Converting Enzyme
 
ICRRC
 
Intramural Clinical Research Review Committee
 
IL
-
1b
 
Interleukin
-
1b
 
IL
-
6
 
Interleukin
-
6
 
IL
-
8
 
Interleukin
-
8
 
IND
 
Investigational New Drug
 
IOP
 
Intraocular Pressure
 
MiCRVO
 
September 19, 2018
 
 
P
ROTOCOL 
A
BBREVIATIONS 
L
IST 
(C
ONTINUED
)
 
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
vii
 
IP
 
Investigational Product
 
IRB
 
Institutional Review Board
 
MCP
-
1
 
Monocyte Chemoattractant Protein
 
MEH
 
Moorfields Eye Hospital
 
MHRA
 
Medicines & Healthcare products Regulatory Agency
 
MI
 
Myocardial Infarction
 
MMP
 
Matrix Metalloproteinase
 
MS
 
Multiple Sclerosis
 
NEI
 
National Eye 
Institute
 
NGF
 
Nerve Growth Factor
 
NIH
 
National Institutes of Health
 
NO
 
Nitric Oxide
 
OB/GYN
 
Obstetrics and Gynaecology
 
OCT
 
Optical Coherence Tomography
 
OHSRP
 
Office of Human Subject Research Protection
 
ONL
 
Outer Nuclear Layer
 
PI
 
Principal 
Investigator
 
PTMS
 
Protocol Tracking and Management System
 
QA
 
Quality Assurance
 
RVO
 
Retinal Vein Occlusion
 
SAE
 
Serious Adverse Event
 
SOP
 
Standard Operating Procedure
 
SPF
 
Sun Protection Factor
 
STZ
 
Streptozotocin
 
SUSAR
 
Serious 
Unanticipated Serious Adverse Reaction
 
TNFa
 
Tumor Necrosis Factor
-
a
 
USP
 
United States Pharmacopeia
 
UV
 
Ultraviolet
 
VA
 
Visual Acuity
 
VEGF
 
Vascular Endothelial Growth Factor
 
YAG
 
Yttrium Aluminum Garnet
 
MiCRVO
 
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
1
 
P
R
É
CIS
 
Objective:
 
Retinal vein occlusions (RVOs) are significant sources of vision loss, affecting mostly 
healthy people over 55 years of age. The common source of vision loss is the macular edema 
accompanying 
the retinal injury. Very recently, studies employing monthly an
ti
-
vascular 
endothelial growth factor (VEGF) treatments have demonstrated a benefit to this line of treatment; 
however, the duration of effectiveness appears to be short lived and the length of time needed for 
these monthly injections remains unknown. 
A hi
stologic study of human retinas with 
RVO
s found 
the presence of activated microglia.
 
Microglia are capable of migrating through the retina to sites 
of inflammation to associate closely with neurons and the vasculature, and are key cellular players 
in the m
ediation
 
of processes of chronic inflammation. For these reasons, microglia represent a 
promising cellular target for forms of therapy that limit the deleterious inflammatory changes 
found in vein occlusions. Minocycline, a second
-
generation tetracycline, 
has been shown to exhibit 
anti
-
inflammatory properties, including microglial inhibition. The objective of this study is to 
investigate the safety and potential efficacy of minocycline as a microglia inhibitor in participants 
with central
 
retinal vein occlu
sion (CRVO).
 
Study Population:
 
A minimum of 
10
 
and a maximum of 
20 participants who meet the eligibility 
criteria may be enrolled. 
Eligibility criteria include: foveal center
-
involved macular edema 
secondary to a CRVO, retinal thickness in the 
central subfield >
 
350 microns as measured by 
optical coherence tomography (OCT); and visual acuity (VA) between 20/
32 and 20/200 in the 
study eye.
 
Design:
 
In this pilot, double
-
masked, randomized 
multi
-
center study
, participants will receive 
monthly bevac
izumab injections for the first three months, followed by PRN dosing. In addition, 
participants will take an oral dose of 100 mg of minocycline or placebo twice daily for 24 months. 
During each monthly visit, participants will have their visual acuity meas
ured and will undergo
 
OCT testing to measure retinal thickness. A
t the 
Month 3 visit and thereafter, participants will be 
evaluated for “improvement” and “worsening” and will be eligible for additional bevacizumab 
treatment and/or investigational product 
(
IP) 
depending on which criteria they fulfill. 
 
Additionally, at Month 12, participants will also be evaluated for “no improvement.”
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
2
 
Outcome Measures:
 
The primary outcome is the difference in mean change in best
-
corrected 
visual acuity (BCVA), as measured
 
in ETDRS letters, between the minocycline and placebo 
groups in the study eye at 12 months compared to baseline. Secondary outcomes include the 
difference between the minocycline and placebo groups in the number of intravitreal bevacizumab 
injections betw
een 12 and 24 months and baseline, changes in mean macular sensitivity as 
measured by microperimetry at 3, 6, 12, 18 and 24 months compared to baseline, the mean change 
in BCVA at 24 months compared to baseline, changes in retinal thickness as measured by 
OCT at 
6, 12, 18 and 24 months compared to baseline, number of participants improving 
≥ 1 logOCT scale 
step at 12 and 24 months compared to baseline, as well as and changes in fluid leakage in the 
macula as demonstrated by fluorescein angiography at 12 and
 
24 months compared to baseline. 
Safety outcomes include the number of participant withdrawals, number and severity of systemic 
and ocular toxicities and the number of adverse events
 
(AEs)
.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
3
 
1.0
 
I
NTRODUCTION
/S
CIENTIFIC 
R
ATIONALE
 
1.1
 
Central Retinal Vein 
Occlusions
 
Retinal vein occlusions are a significant source of vision loss, affecting mostly healthy people over 
55 years of age. The common source of vision loss is the macular edema accompanying 
the retinal 
injury. The two main types of retinal vein occl
usions are central retinal vein occlusions (CRVO) 
and 
branch
 
retinal vein occlusions (BRVO). 
The pre
valence of CRVO is approximately 0.1%.
1,2
 
The standard
-
of
-
care for CRVO is even more limited than for BRVO. While optic nerve 
sheathotomy and other invasive measures have been tried, these interventions have not been 
successfully proven in a large randomized clinical trial. Very recently the Cent
ral Retinal Vein 
OcclUsIon Study: Evaluation of Efficacy and Safety (CRUISE), a phase III multicenter trial, 
reported 
six
-
month outcome results demonstrating efficacy of intravitreal ranibizumab injections 
for the treatment of CRVO.
3
 
The CRUISE study, while encouraging, only has 
six
-
month r
esults 
published and requires monthly intravitreal injections with no clear treatment endpoint. 
Ranibizumab has very recently gained FDA approval for the indication of vein occlusions and the 
labeling includes recommendations for monthly intravitreal injec
tions
.
 
The fundamental cause of macular edema associated with retinal vein occlusions is not understood 
completely, but it is increasingly clear that its pathophysiology extends beyond microvascular 
disease to involve immune mediators in the retina. While 
hydrostatic stress following the 
 
break
-
down of the blood
-
retinal barrier (BRB) can partly contribute to retinal edema, tissue 
responses to hypoxia are also likely to play a role. In the aftermath of a retinal vein occlusion, 
tissue hypoxia induces the exp
ression of several cytokines, including monocyte chemoattractant 
protein (MCP
-
1), leading to the activation of inflammatory cells, such as macrophages and 
microglia, which are then attracted to the hypoxic retinal areas.
4
 
Activated microg
lia release 
 
TNF
-
α which triggers the production of interleukin
-
8 (IL
-
8), VEGF, basic fibroglast growth factor 
(FGF) and MCP
-
1 in retinal vascular cells and glial cells adjacent to the microvessels.
5
 
A study on 
patients with BRVO examined the concentrations of VEGF and interleukin
-
6 (IL
-
6) i
n the aqueous 
humor and found that these cytokine levels were increased in the setting of retinal vein occlusion.
6
 
 
Further, a histologic study of human r
etinas with retinal vein occlusions found numerous cluster 
of differentiation
-
68 (CD
-
68) positive cells surrounding the vasculature indicating the presence of 
activated microglia.
7
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
4
 
Inflammation may represent an early adaptive response to metabolic derangements in the ischemic 
retina; over time
;
 
howev
er, it leads to progressive vascular damage results, culminating in macular 
edema and neovascularization.
8
 
As such, there may be a feasible therapeutic rationale to broadly 
limit and down
-
regulate the level of microglia
-
mediated chronic inflammation in the treatment of 
RVOs.
 
1.2
 
Current Treatments of CRVO
 
Unlike 
branch
 
retinal vein occlusions, CRVOs did not demonstrate an improvement in visual 
acuity with focal laser photocoagulation.
9
 
Several more invasive therapies have been pursued 
including optic neurotomy and sheathotomy. However, none have shown efficacy in a randomized 
controlled clinical trial. In fact, a review of CRVO intervention treatments in 2007 concluded th
at 
there was
 
limited evidence for any intervention to improve visual acuity in patients with CRVO.
10
 
Recently, phase III results of the CRUISE study, have demonstrated efficacy of monthly injections 
of ranibizumab for treatment of central retinal vein occlusions.
3
 
And in late June 2010, the FDA 
approv
ed ranibizumab for use in the treatment of retinal vein occlusions.
 
However, while the treatment of monthly injections appears beneficial in the short term, the longer 
term result of this course of treatment is unknown. Also unknown, is the number of injec
tions 
required, and the durability of these injections. While being a major breakthrough in the field of 
treatment of these retinal conditions, monthly anti
-
VEGF injections still have limitations for 
treating this disease.
 
We propose to study minocycline a
s a microglia inhibitor which can modulate the activation of 
microglia, alter the cytokine profile present, and thus may be useful in the treatment of CRVO.
 
1.3
 
Role of Microglia
 
Retinal microglia, derived from the monocytic lineage, are resident cells in the 
healthy retina, and 
may be construed as representatives of the immune system in the immune
-
privileged environment 
of the retina. 
Microglia are related to macrophages but are a distinct entity
11
 
comprising 
approximately 5% to 20% of the total glial cell population in the central nervous system (CNS).
12
 
Microglia in the CNS are important sources of inflammatory cytokines and chemokines, and are 
the primary cellular mediators of imm
une function.
13
 
Most of the factors released by activated 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
5
 
microglia are proinflammatory and neurotoxic, including cytokines tumor necrosis factor
-
a 
(TNFa) and interleukin
-
1b (IL
-
1b), free radicals such as NO and superoxide, fatty acid metabolites 
such as eico
sanoids, and quinolinic acid.
14
 
The activation of microglia has been implicated in the 
pathogenesis of many neurodegenerat
ive diseases including Alzheimer’s, Parkinson’s disease, 
HIV
-
related dementia, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and prion 
diseases.
15
 
The cytokines released by activated microglia are thought to speed neurodegeneration. 
Microglia have also been implicated 
in ischemic and mechanical injury to the brain.
16
 
In the retina, 
retinal glial cells consist of macroglia (Müller cells and astrocytes) and microglia. Mi
croglia are 
able to migrate in various retinal disease states. In photic injury, microglia migrate from the inner 
retinal layers to the outer nuclear layer (ONL) and also into the subretinal space.
17,18
 
In sites of 
inflammation, these cells migrate through the retina to closely associate with neurons and the
 
vasculature, and are key cellul
ar players in the mediation of processes of chronic inflammation. 
As such, it is likely that retina microglia play an important role in the 
inflammatory et
iology of 
diabetic retinopathy.
 
1.4
 
Role of Microglia in Retinal Vein Occlusions
 
There is accumulating ev
idence that retinal microglia are indeed associated with inflammation in 
the retina in conditions such as diabetic retinopathy and RVOs. While diabetic retinopathy is often 
thought of as a vasculopathy, there is a growing body of evidence to suggest that c
hanges in the 
retinal neurons precede vascular changes.
19
 
Microglia function has been investigated in a diabetic 
animal model where diabetes was induced in rats with the inj
ection of streptozotocin (STZ).
 
Animal models of diabetes have indicated a role of microglia activation in diabetic retinopathy. 
 
In a
 
histologic study of microglia in eyes with diabetic retinopathy,
 
Zeng et al. reported that 
microglia increase in number and exhibit hypertrophic features
 
as well as an up
-
regulation of 
markers in diseased states and marked microglia surrounding the retinal vasculature, labeled 
“microglia perivasculitis” in further stages of disease.
20
 
This may lead to early fluorescein leakage 
present before frank vasculopathy is noticed clinically both in diabetic retinopathy and vein 
occlusion injury.
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
6
 
Animal models of ischemia/reperfusion injur
y mimics the mechanism of injury occurring in 
RVOs. Shin et al. used both an ischemia/reperfusion model as well as a venous cauterization 
method to demonstrate that microglia become activated under these circumstances and migrate to 
the inner plexiform lay
er near blood vessels.
21
 
Further resea
rch by Lin et al. on an ischemia/
 
reperfusion model in rats have shown that not only are microglia activated in this model, but also 
that they can be inhibited by minocycline.
22
 
In their model, they demonstrated a signifi
cant 
treatment effect of treatment in rats with minocycline inhibiting the vascular permeability response 
by inhibiting microglia.
 
Indeed, focal laser photocoagulation, the long
-
time standard
-
of
-
care treatment for 
Diabetic 
Macular Edema (
DME
)
 
and for 
branc
h
 
retinal vein occlusion (BRVO), recently has been found to 
induce prompt changes in the morphology and behavior of retinal microglia, and may thus also 
involve microglia in their therapeutic effect.
23
 
For these reasons, microglia represent a promising 
cellular target for forms of therapy that limit the deleterious inflammatory changes found in vein 
occlusions. While therapeu
tic agents that specifically inhibit individual pro
-
inflammatory 
molecules one at a time may have efficacy, an approach that targets the cellular mediator, the 
microglia cell, may have broader and more relevant effects.
 
1.5
 
Minocycline as a Microglia Inhibitor
 
1.5.1
 
Minocycline
 
Minocycline is a second
-
generation tetracycline, which has anti
-
inflammatory properties that are 
separate from its anti
-
microbial properties. Minocycline has high lipophilicity, which leads to both 
excellent bioavailability and ability to cros
s the blood
-
brain barrier
24
 
and appears to inhibit the 
activation of microglia, but not astrocytes.
25
 
The mechanism of neuroprotection by minocycline is 
lik
ely several
-
fold and includes: anti
-
inflammatory effects, reduction of matrix metalloproteinase 
(MMP) activity,
26
 
and decrease in NO production, ultimately leading to an inhibition of microglia 
and of cell death.
27
 
Minocycline can exert its anti
-
inflammatory effects on microglia in culture, 
inhibiting their proliferation and release of IL
-
1B, IL
-
6, TNF
-

, NO secretion, and 
 
NGF
-
production leading to neuroprotection with
 
the inhibition of cell death.
28
-
32
 
Minocycline has 
been also found to inhibit induction of IL
-
1b
-
converting enzyme (ICE) mRNA
25
 
which means that 
minocycline may function by reducing cytotoxic properties o
f microglia which can be activated 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
7
 
by ischemia and neuroexcitation. In addition, minocycline can also help prevent cytokine
-
induced 
activation of microglia and prevent further production of proinflammatory stimuli.
 
1.5.2
 
Preclinical Studies with 
Minocycline
 
In animal models of global and focal cerebral ischemia, traumatic brain and spinal injury, 
minocycline treatment showed a reduction in lesion size in conjunction with the inhibition of 
microglial cells.
33
-
36
 
In rodent models of spinal cord injury, treatment with minocycline not only 
reduced lesion size and improved histological parameters but also improved neurological function 
such as hind
 
limb function and strength.
37
 
Minocycline has also been studied in the context of ocular diseases. In mouse models of glaucoma, 
minocycline successfully decreased microglial activat
ion and retinal ganglion cell axonal transport 
and 
improved 
optic nerve integrity.
38
 
Minocycline was effective in decreasing retinal microglia 
activation in culture.
39
 
In models of inherited and light
-
induced retinal degeneration, minocycline 
was effective in delaying photoreceptor cell death.
39,40
 
As mentioned above, minocycline reduces 
apoptotic cell death in
 
mouse models of diabetic retinopathy.
32
 
Animal studies have also indicated 
that inhibiting microglia activation with minocycline was useful in decreasing the level of pro
-
inflammatory mediators and preventing diabetes
-
induced cell death in th
e retina.
32
 
In particular, 
addition of minocycline to TNF
-
alpha
-
activated microglia was found to prevent the r
elease of 
COX
-
2, an enzyme important in prostaglandin synthesis and is a robust marker of inflammation.
32
 
 
Ult
imately, diabetic rats do demonstrate an increased rate of apoptosis, as evidenced by increased 
caspase
-
3 activity, and minocycline has been shown to decrease that activation.
32
 
1.5.3
 
Clinical Use and Clinical Studies with Minocycline
 
Minocycline is a member of the tetracycline family of antibiotics that has good CNS bioavailability 
following oral administration. It is 
FDA
-
approved for treating many infections including 
skin 
infections caused 
by 
Staphylococcus
 
aureus
 
and is often used in ophthalmology to treat blepharitis 
and ocular 
rosacea. It has a favorable side
-
effect profile, although it should not be used in 
pregnancy as the use of tetracycline class of drugs during tooth development may cause permanent 
discoloration of the teeth.
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
8
 
Minocycline is used widely and has been shown 
to be well tolerated when used at the 
 
FDA
-
approved doses proposed in this study. Based on studies examining the adverse events (AEs) 
reported between 1998 and 2003, and the number of prescriptions for minocycline, the rate of AEs 
has been reported as 72 A
Es per million prescriptions averaging to 
13 per million per year.
41
 
 
The majority of these events were gastrointestinal upset, photosensitivity, hyperpigmentation and 
tooth discoloration.
41
 
Its application in clinical trials as an anti
-
microglia agent include a large clinical trial of 
 
152 patients wit
h acute stroke in which patients treated with 200 mg minocycline for 
five
 
days had 
a significantly better neurological outcome compared with placebo.
27
 
Other ongoing clinical 
studies include the use of minocycline to decrease symptom progression in Huntington’s disease 
([STUDY_ID_REMOVED]), and to provide neuroprotective effects in Parkinson’s disease (NCT0006319
3) 
and in ALS ([STUDY_ID_REMOVED]).
 
A current clinical trial, conducted by the Penn State Diabetic Retinopathy Center, is commencing 
recruitment to examine the effects of a related tetracycline, doxycycline, in its ability to slow the 
deterioration or improve ret
inal function and/or induce regression, or slow progression, of diabetic 
retinopathy ([STUDY_ID_REMOVED]).
 
2.0
 
S
TUDY 
O
BJECTIVE
 
The study objective is to investigate the safety and potential efficacy of minocycline, a microglia 
inhibitor, in the treatment of CRVO.
 
3.0
 
P
ARTICIPANTS
 
The accrual ceiling is
 
20 participants who meet the eligibility criteria
.
 
3.1
 
Participant Eligibility Criteria
 
3.1.1
 
Inclusion Criteria
 
To be eligible, the following participant
-
level inclusion criteria must be met, where applicable.
 
1.
 
Participant is 18 years of age or older.
 
2.
 
Participant must understand and sign the protocol’s informed consent document.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
9
 
3.
 
Female participants of childbearing potential (see Appendix 1 for definition) must not be 
pregnant or breast
-
feeding and must be willing
 
to undergo 
serum (BRC sites only) and 
urine
 
pregnancy tests throughout the study.
 
4a.
 
For the NEI Site: 
Female participants of childbearing potential (see Appendix 1 for 
definition) and male participants able to father children must have (or have a partne
r who 
has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must 
agree to practice two acceptable methods of contraception throughout the course of the 
study and for one week after study medication discontinuation (based on the 
half life of 
minocycline which is 11
-
22 hours). 
Acceptable methods of contraception include:
 

 
hormonal
 
contraception (i.e., birth control pills*, injected hormones, dermal patch or 
vaginal 
ring),
 

 
intrauterine device,
 

 
barrier methods (diaphra
gm, condom) with
 
spermicide, or
 

 
surgical sterilization (hysterectomy or tubal ligation).
 
*Oral 
birth control pills must be used with caution as minocycline decreases the 
effectiveness of some oral contraceptives. Participants already taking oral contraceptives 
may continu
e to use them, but must agree to use at least one other method of birth control 
while on study.
 
4b.
 
For the BRC Sites:
 
Female participants of childbearing potential (see Appendix 1 for 
definition) and male participants able to father children must have 
(or have a partner who 
has) had a hysterectomy or vasectomy,
 
or
 
be completely abstinent from intercourse
.
 
 
Male participants
 
or male partners 
(
of female participants
)
 
who have not had a vasectomy 
or are not abstinent are required to use a condom with sperm
icide
 
throughout the course of 
the study and for one week after study medication discontinuation (based on the half life 
of minocycline which is 11
-
22 hours). 
F
emale participants of childbearing potential or 
female partners (of male participants) of childb
earing potential must practice one of the 
below
 
a
cceptable methods of contraception 
throughout the course of the study and
 
for one 
week after s
tudy medication discontinuation
:
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
10
 

 
hormonal
 
contraception (i.e., birth control pills*, injected hormones, dermal pa
tch or 
vaginal ring),
 

 
intrauterine device,
 

 
barrier methods (
e.g., 
diaphragm) with spermicide, or
 

 
surgical sterilization (hysterectomy or tubal ligation).
 
Abstinence is only acceptable when it is the participant’s preferred and usual lifestyle 
choice. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post
-
ovulation 
methods) and withdrawal are not acceptable methods of contraception.
 
*Oral 
birth control pills must be used with caution as minocycline decreases the 
effectiveness of som
e oral contraceptives. Participants already taking oral contraceptives 
may continue to use them, but must agree to use at least one other method of birth control 
while on study.
 
It should be noted that two forms of contraception (as specified above) will b
e used by 
sexually active participants for the duration of the study and for one week after study 
medication discontinuation.
 
5.
 
Participants must agree to notify the study investigator or coordinator if any of their doctors 
initiate a new medication during t
he course of this study.
 
6.
 
Participant must have normal renal function and liver function
, or have mild abnormalities 
not above grade 1 as defined by the Common Terminology Criteria for 
AE
s v4.0 (CTCAE).
 
7.
 
Participant must agree to minimize exposure to sunligh
t or artificial UV rays and to wear 
protective clothing, sunglasses, and sunscreen (minimum SPF 15) if s/he must be out in the 
sun.
 
8.
 
Participant has at least one eye that meets the study eye criteria listed in Section 3.2 below.
 
3.1.2
 
Exclusion Criteria
 
A partici
pant is not eligible if any of the following exclusion criteria are present.
 
1.
 
Participant is in another investigational study and actively receiving 
IP
 
for CRVOs.
 
2.
 
Participant is unable to comply with study procedures or follow
-
up visits.
 
3.
 
Participant has a k
nown hypersensitivity to sodium fluorescein dye.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
11
 
4.
 
Participant has a condition that, in the opinion of the investigator, would preclude 
participation in the study (e.g., unstable medical status including blood pressure and 
glycemic control).
 
5.
 
Participant has 
a history of chronic renal failure requiring dialysis or kidney transplant.
 
6.
 
Participant has a history of 
chronic 
hepatitis or liver failure.
 
7.
 
Participant has an allergy or hypersensitivity to minocycline or any drug in the tetracycline 
family.
 
8.
 
Participant i
s currently taking a tetracycline medication.
 
9.
 
Participant is taking any medication that could adversely interact with minocycline such as 
m
ethoxyflurane.
 
10.
 
Participant has a blood pressure of >
 
180/110 (systolic above 180 
OR
 
diastolic above 110).
 

 
If blood pressure is brought below 180/110 by anti
-
hypertensive treatment, the 
participant can become eligible.
 
11.
 
Participant 
is currently being
 
treat
ed
 
with systemic 
anti
-
VEGF agents or 
systemic 
steroids.
 
12.
 
Participant had a cerebral vascular event (CVA) or myocardial infarction (MI) within three 
months prior study entry.
 
13.
 
Participant has a history of thyroid cancer.
 
3.2
 
Study Eye Eligibility Criteria
 
The participant must hav
e at least one eye meeting all inclusion criteria and none of the exclusion 
criteria listed below.
 
3.2.1
 
Study Eye Inclusion Criteria
 
1.
 
The study eye has a best
-
corrected ETDRS visual acuity score between 78 and 34 letters 
(i.e., between 20/32 and 20/200)
.
 
2.
 
The stu
dy eye shows definite retinal thickening due to a CRVO based on clinical 
examination involving the center of the macula that is not refractory to further therapy as 
based on the investigator’s clinical judgment. CRVO is defined as an eye that had retinal 
h
emorrhage or other biomicroscopic evidence of RVO (e.g., telangiectatic capillary bed) 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
12
 
and a dilated (or previously dilated) venous system in at least three quadrants of the retina 
drained by the affected vein.
 
3.
 
The study eye has retinal thickness in the ce
ntral subfield on baseline
 
OCT measurement 
>
 
350 microns, as measured by Zeiss Cirrus spectral domain OCT, or an equivalent retinal 
thickness on a similar OCT machine.
 
4.
 
The study eye has media clarity and pupillary dilation sufficient for adequate fundus 
ph
otographs. Furthermore, the participant must be able to cooperate during the procedure 
for accurate fundus photographs.
 
3.2.2
 
Study Eye Exclusion Criteria
 
1.
 
Macular edema is considered to be 
due to a cause other than CRVO.
 
2.
 
An eye should
 
not be considered eligible 
if:
 

 
The macular edema is considered to be related to cataract extraction
,
 
or
 

 
Clinical examination and/or OCT suggest that vitreoretinal interface disease (e.g., a 
taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular 
edema
,
 
or
 

 
Clinical examination, medical history and/or fluorescein angiography suggest that 
diabetic retinopathy is the primary cause of the edema.
 
3.
 
The study eye has a history of a recurrent RVO.
 
4.
 
The study eye has a history of RVO present for >18 months.
 
5.
 
A 
brisk afferent pupillary defect (APD) is present in the study eye.
 
6.
 
An ocular condition (other than RVO) is present such that, in the opinion of the 
investigator, visual acuity would not improve from resolution of macular edema 
 
(e.g., foveal atrophy, pigme
ntary changes, dense subfoveal hard exudates, laser scar at
 
fovea, non
-
retinal condition).
 
7.
 
An ocular condition (other than RVO) is present that, in the opinion of the investigator, 
might affect macular edema or alter visual acuity during the course of the 
study 
 
(e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, 
Irvine
-
Gass Syndrome, etc.).
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
13
 
8.
 
A substantial cataract that, in the opinion of the investigator, is likely to be decreasing 
visual acuity by three lines or more 
(i.e., cataract would be reducing acuity to 20/40 or 
worse if eye was otherwise norma
l) is present in the study eye.
 
9.
 
The study eye has had panretinal or sectoral scatter photocoagulation (PRP) within four 
months prior to study entry.
 
10.
 
The study eye has had 
pars plana vitrectomy within six months prior to study entry.
 
11.
 
The study eye has undergone major ocular surgery (including cataract extraction, scleral 
buckle, any intraocular surgery, etc.) within three months prior to study entry.
 
12.
 
A yttrium aluminum garne
t (YAG) capsulotomy has been performed on the study eye 
within two months prior to study entry.
 
13.
 
The study eye has had treatment <
 
3 months prior to study entry of intravitreal or periocular 
steroid injections.
 
14.
 
The study eye has had treatment < 28 days prio
r to study entry of intravitreal anti
-
VEGF 
agents.
 
3.2.3
 
Study Eye Selection Criteria in Cases of Bilateral Disease
 
If both eyes of a participant meet the criteria described in Sections 3.2.1 and 3.2.2, the study eye 
will be determined at the investigator’s disc
retion.
 
4.0
 
S
TUDY 
D
ESIGN AND 
M
ETHODS
 
4.1
 
Study Overview
 
This is a pilot, double
-
masked, randomized, 
multi
-
center study to investigate the safety and 
potential efficacy of minocycline as a microglia inhibitor in participants with CRVO who are 
concurrently being tre
ated with standard
-
of
-
care anti
-
VEGF (bevacizumab) intravitreal injections. 
This study is designed not to determine efficacy but rather to generate preliminary data to support 
a fully powered phase III study.
 
4.2
 
Recruitment
 
Up to 20 participants will be recru
ited from the NEI clinic and BRC sites, collectively. 
 
The recruitment totals are not fixed at either the NEI or BRC sites.
 
NIH recruitment will occur by s
elf
-
referral and referral from outside physicians will be permitted. 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
14
 
A letter will be provided to local ophthalmologists to assist with recruitment. 
A recruitment flyer 
will be posted at community gathering places including but not limited to: hospitals, libraries, 
senior centers, senior housing facilities, area metro and bus stops, websites, newspapers and 
throughout the NIH campus. 
NIH investigators 
from this study worki
ng at the Veterans Affairs 
hospital will provide information to patients in the V
eterans 
A
ffairs
 
eye clinic, but will not perform 
a formal assessment of eligibility or conduct any part of the informed consent process at the 
V
eterans 
A
f
fairs
 
hospital. Potentially interested patients will contact the investigators at a later 
time. Contact information from V
eterans 
A
ffairs
 
patients will be provided to the NIH investigators 
only if the patient specifically requests that someone call them to
 
set up the initial visit. 
 
The interaction will be documented in the medical record at the V
eterans 
A
ffairs
 
clinic.
 
Participants 
at the BRC sites 
will be identified following attendance at routine appointments or 
sent a recruitment letter from existing da
tabases of patients diagnosed with 
C
RVO and who 
routinely attend the BRC
 
sites
 
for treatment.
 
4.3
 
Screening
 
Potential p
articipants 
at the NEI 
will be screened under the NEI screening (08
-
EI
-
0102) or 
evaluation and treatment protocol (08
-
EI
-
0169) to establish
 
e
ligibility. The participant must have 
an active signed consent for one of the above mentioned protocols on file for baseline examinations 
to occur. Baseline examinations will be performed as outlined in Appendix 2. Laboratory measures 
may be performed with
in 42 days of enrollment. Optical coherence tomography (OCT), color 
fundus photography and 
fluorescein angiography 
may be performed within seven days of the 
baseline visit. All other baseline examinations must occur on the day the participant reviews and 
s
igns this protocol’s consent form, unless specified in Appendix 2. Treatment with the 
IP
 
(minocycline or placebo) cannot occur until the participant has reviewed and signed this protocol’s 
consent form.
 
Potential participants from the BRC sites will be screened under this study protocol. 
 
The participant must have signed this protocols consent form for any study examinations to occur. 
For the BRC sites, it
 
is expected that 
the baseline examinations
 
can be
 
completed in one clinic visit 
over one day. 
If the baseline
 
examinations cannot be performed in one clinic visit over one day, it 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
15
 
is acceptable that the baseline examinations be completed at 
subsequent clinic visits
, if 
scheduled 
within 
fourteen
 
days of t
he first visit.
 
4.4
 
Randomization, Masking and Unmasking
 
After the participant is determined eligible and has completed the informed consent process, the 
group will be assigned based on a predetermined randomization schedule developed by the 
Coordinating Cente
r. Randomization will be stratified by site.
 
Randomization must occur on the same day as the initial administration of 
IP
 
while the participant 
and the ophthalmologist are present and will not be permitted any time before. 
 
Participant eligibility must be 
confirmed before a participant is randomized. 
P
articipants will be 
randomized to one of two groups with equal probability of equal numbers of participants in each 
group: minocycline or placebo. 
Participants must continue to receive the same treatment regim
en 
to which they were assigned for the duration of the study.
 
All clinic staff and participants will be masked to group assignments. Only designated pharmacy 
personnel, select individuals at the 
Emmes
 
Corporation, and the NEI Data and Safety Monitoring 
Committee (DSMC) will have access to the group assignments.
 
Participants will be unmasked if deemed clinically necessary by the examining physician and if 
the study Principal Investigator (PI) and DSMC C
hair are in agreement. 
In the case of a medical 
emergency, the examining or treating physician will have the final decision and unilateral right for 
unmasking. 
A request for unmasking, after approval by the PI and the DSMC Chair, will be made 
to the 
C
oordi
nating 
C
enter 
personnel, who will inform the PI and the DSMC Chair of the group 
assignment. Attempts should be made to maintain the masking of the investigators prior to the 
study
-
wide unmasking. Unmasking will be recorded on an 
AE
 
form. All instances of u
nmasking 
must be reported to the ICRRC, the CNS IRB and the DSMC.
 
4.5
 
Study Design and Procedures
 
For the NEI Site: 
The study duration will be 24 months. During this period, p
articipants will be 
instructed to take the 
IP
 
(either placebo or minocycline 100 mg c
apsule) twice daily. The primary 
outcome will be assessed at Month 12, and secondary outcomes will be assessed at 6, 12, 18 and 24 
months. Visits will occur at baseline, and then monthly or as clinically indicated. 
The study will 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
16
 
require a minimum
 
of 
25 ap
pointments (baseline and Months 1
-
24). All appointments must be 
conducted within a window of ± 
seven 
days from the target day. The tests 
scheduled at each visit 
will be completed in one day. At each visit, the participant will undergo a review of systems a
nd 
an assessment of safety variables. A complete ophthalmologic examination will be performed at 
each visi
t to measure outcome variables.
 
During each clinic visit, 
participants will have their visual acuity measured and will undergo OCT 
testing to measure 
retinal thickness.
 
For the BRC Sites
: 
The study duration will be
 
approximately
 
24 months. During this period, 
p
articipants will be instructed to take the 
IP
 
(either placebo or minocycline 100 mg capsule) twice 
daily. The primary outcome will be assessed at Month 12, and secondary outcomes will be assessed 
at 6, 12, 18 and 24 months. Visits will occur at baseline, and then monthly or as clinically indicated. 
T
he study will require a minimum
 
of 2
6
 
appointments (baseline and Months 1
-
24
 
and safety 
follow
-
up
). All appointments must be conducted within a window of ± 
seven 
days from the target 
day
, except for the safety follow
-
up visit which must occur at least five
 
days after the cessation of 
IP
. The tests 
scheduled at each visit 
are expected to
 
be completed in one day
, 
with the exception 
of the B
aseline visit, Month 12 visit and Month 24 visit
. 
If the baseline
 
examinations cannot be 
performed in one clinic visit ov
er one day, it is acceptable that the baseline examinations be 
completed at 
subsequent clinic visits
, if 
scheduled within 
fourteen
 
days of the first visit.
 
If the 
Month 12 and Month 24 examinations cannot be performed in one clinic visit over one day, it i
s 
acceptable that the examinations be completed at 
subsequent clinic visits
, if 
scheduled within 
seven
 
days of the first visit
. At each visit, the participant will undergo a review of systems and an 
assessment of safety variables. A complete ophthalmologic
 
examination will be performed at each 
visit 
(except for the safety follow
-
up visit)
 
to measure outcome variables.
 
If the B
aseline visit, 
Month 12 visit, or Month 24 visit are conducted over more than one day, BCVA, OCT and 
microperimetry testing must be c
onducted on the day of the injection.
 
During each study visit, with the exception of the Month 24 visit
 
and safety follow
-
up visit at the 
BRC sites
, 
IP
 
will be dispensed to the participant unless the treatment is deemed to be “worsening” 
or to offer “no im
provement,” and the participant and investigator decide to stop 
IP
. 
 
An information sheet outlining instructions on taking the study medication and concomitant 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
17
 
medications will be distributed to participants and discussed in detail by study personnel. 
 
They will be asked to inform any physician who is prescribing new medications that they are 
currently taking minocycline. In addition, the participants will be asked to inform a study team 
member if a new medication is prescribed to them.
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
18
 
Participant compliance with 
IP
 
will be prompted through ongoing encouragements and reminders 
during study visits and scheduled and unscheduled telephone contacts. Compliance will be 
assessed by pill counts conducted during study visits and the participant’
s pill diary. 
 
Once identified, occurrences in which the computed compliance rate between study visits falls 
below 50% will be reported as a protocol deviation to the CNS IRB within two weeks using PTMS.
 
4.5.1
 
Treatment Prior to Month 3
 
At baseline, the particip
ant will receive an injection of 1.25mg bevacizumab, an anti
-
VEGF agent, 
and also start the randomized 
IP
. At Months 1 and 2, the participant will again receive bevacizumab 
injections in the study eye and continue the rando
mized 
IP
.
 
4.5.2
 
Treatment Beginning at 
Month 3
 
Visual acuity and macular edema will be evaluated at study visits to determine further treatment. 
Starting at Month 3 and at every visit thereafter, the following scenarios will be considered. 
 
(Also refer to Figure 1.) The participant will be rein
jected with bevacizumab unless the participant 
meets the “improvement,” “worsening
,
”
 
“new steady state”
 
or “no improvement” criteria defined 
in Appendix 
3
.
 
Scenario 1: 
If the participant meets the “improvement” criteria defined in Appendix 
3
, the 
participant will continue to take the 
IP
, but the bevacizumab injection 
will be withheld at that visit.
 
Scenario 2:
 
If the participant meets the “worsening” criteria defined in Appendix 
3
, the participant 
will be offered any therapy available at the 
discretion of the treating investigator, including:
 
a.
 
Anti
-
VEGF Treatment
 
b.
 
Intravitreal or Periocular Steroid Injections
 
Scenario 3:
 
If the participant does not meet the “improvement” or “worsening” criteria, but meets 
the “new steady state” criteria defined 
when the central subfield thickness remains 
≥
 
300 microns 
on OCT but has not changed > 25 microns over the last three consecutive injections (also defined 
in Appendix 
3
), the treating investigator physician will have the discretion to hold bevacizumab 
inje
ctions until the OCT changes (worsens) by > 25 microns from this “new steady state” level.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
19
 
At the Month 12 visit and at every visit thereafter, Scenarios 1
,
 
2
 
and 3
 
will be considered as well 
as the following scenario, which allows for a study physician to
 
determine whether there has been 
“no improvement” in the participant’s condition:
 
Scenario 
4
: If the participant meets the “no improvement” criteria defined in Appendix 
3
, or if the 
investigator’s clinical impression is that there has been no improvement 
in the study eye, the 
participant will be offered therapy at the discretion of the treating investigator. The decision to 
 
re
-
inject the participant with bevacizumab (the anti
-
VEGF agent) will be made by the treating 
investigator after consulting with the 
participant. The decision to continue the 
IP
 
will also be made 
by the treating investigator after consulting with the participant.
 
MiCRVO
 
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
20
 
Figure 1. Treatment Scenarios
 
 
 
 
Enrollment = M
onth 0
 
-
 
Confirm eligibility
 
-
 
Review/sign consent form
 
-
 
Give bevacizumab
 
injection
 
-
R
andomize
 
participant
 
to 
investigational product
 
Month
s
 
1, 2
 
-
 
Give bevacizumab
 
injection 
 
-
Dispense
 
randomized 
investigational product to 
participant
 
Is this visit 
M
onth 12
 
or after
?
 
no
 
yes
 
Does p
ar
t
icipant
 
meet criteria 
for 
“no improvement
?
”
 
-
 
Treat participant
 
at 
the 
discretion of treating
 
investigator
 
no
 
-
 
Dispense randomized
 
investigational product
 
-
 
H
old 
bevacizumab 
injection
 
-
 
Treat participant
 
at 
the 
d
iscretion of 
treating 
investigator
 
no
 
Does the p
ar
t
icipant
 
meet 
criteria for 
“improvement
?
”
 
yes
 
yes
 
Does
 
p
ar
t
icipant
 
meet 
criteria for 
“worsening
?
”
 
no
 
yes
 
Month
s
 
3 and thereafter
 
-
 
Consult decision tree to the 
right
 
Does participant meet criteria for “new 
steady state?”
 
yes
 
-
Dispense investigational 
product
 
-
Investigator physician discretion 
to hold bevacizumab injection
 
no
 
-
 
Dispense randomized 
investigational product
 
-
 
Give
 
bevacizumab 
injection
 
MiCRVO
 
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
21
 
4.6
 
Ocular and Systemic Evaluations
 
Following is a detailed list of the study procedures. All of the study procedures, with the exception 
of the administration of the 
IP
, are typical components of the clinical care required for a participant 
with macular edema secondary to CRVO. Examinations
 
are performed at the study visits as 
indicated in th
e study flowsheet (Appendix 2).
 
1.
 
Dispense 
IP
 
and
 
provide an information sheet outlining instructions on taking 
IP
 
and 
concomitant medications and pill diary
 
2.
 
Drug Accountability Review
 
3.
 
Evaluation for “impr
ovement,” “worsening” and “no improvement” defined in 
 
Appendix 
3
 
4.
 
Medical/Ophthalmic History
 
5.
 
Physical Examination
 
6.
 
Vital Signs
 
7.
 
Review of Systems
 
8.
 
Allergies Assessment
 
9.
 
Concomitant Medications Assessment
 
10.
 
Adverse Event Assessment
 
11.
 
Best
-
Corrected Visual Acuity (B
CVA) and Manifest Refraction using Early Treatment 
Diabetic Retinopathy Study (ETDRS) Methods
 
12.
 
Slit Lamp Examination
 
13.
 
Dilated Fundus Examination
 
14.
 
Color Fundus Photography (CFP)
 
15.
 
Intraocular Pressure (IOP)
 
16.
 
Spectral Domain Optical Coherence Tomography (OCT)
 
17.
 
Micr
operimetry
 
18.
 
Fluorescein Angiogram (FA)
 
19.
 
Acute Care Panel
1
 
20.
 
Hepatic Panel
1
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
22
 
21.
 
Complete Blood Count (CBC)
1
 
22.
 
Thyroid Function Test
1,2
 
 
23.
 
Thyroid Palpation
3
 
24.
 
Pregnancy Test for Women of Childbearing Potential (
serum and 
urine)
1
, 4
 
(see Appendix 
1 for definition)
 
1 
 
All abnormal values or positive tests will be reported to the participant’s primary care 
physician, with the participant’s permission.
 
2 
 
Participants with abnormal thyroid function test results will be referred to an 
en
docrinologist.
 
3
 
Abnormal findings during a thyroid palpation will be followed by a referral to an 
endocrinologist.
 
4
 
Applicable to the BRC sites only: A serum pregnancy test will be performed with 
 
24 hours prior to initiation of minocycline
.
 
After initiation of contraception, urine 
pregnancy tests will be conducted; however, a serum test will be performed anytime a 
urin
e test result creates doubt
.
 
If any medications need to be initiated or altered to address any change in lab values, or symptoms, 
the participant’s primary care doctor will be contacted, or the medical consultant team will be 
contacted to evaluate the part
icipant and to prescribe the appropriate medications.
 
4.6.1
 
Reporting of Expected Events
 
It is anticipated that participants in this study will occasionally miss or fail to complete an assessment, 
procedure or study visit. These omissions will be considered expe
cted events and not protocol 
deviations provided they are infrequent and do not include data needed to assess safety or the primary 
study outcome. 
If such an event is identified, the PI will submit a report to the IRB within two weeks 
using PTMS.
 
Cumulativ
e proportions of these missed events in the study population will be presented to the IRB 
annually. In addition, these rates will be 
calculated and 
monitored 
biannually 
by the DSMC.
 
The following are considered deviations:
 

 
An individual misses more 
than 15% of the required study assessments/procedures,
 

 
An individual misses more than 15% of the required study visits,
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
23
 

 
An individual completes more than 15% of the required study visits outside of the visit 
window,
 

 
Collectively, participants missed 
more than 15% of a specific assessment/procedure,
 

 
Collectively, participants missed more than 15% of the required study visits, or
 

 
Collectively, participants complete more than 15% of the required visits outside the visit 
window.
 
If 
the 
total number of 
exp
ected 
items (study visits or study assessments/procedures) is less than
 
or 
equal to
 
16,
 
and two
 
or more
 
items are
 
miss
ing, a deviation will be reported.
 
If the total number 
of 
items 
expected is greater than 16,
 
and
 
15% 
or more items 
are miss
ing, a deviatio
n will be reported
.
 
The total number of items (study visits or study assessments/procedures) for an individual and 
collectively will be calculated cumulatively. If a protocol deviation (as defined above) is identified, 
the PI will submit a report to the IR
B using PTMS.
 
4.7
 
Study and Concomitant Therapy
 
4.7.1
 
Minocycline Formulation at 
Pine Pharmaceuticals
 
Pine Pharmaceuticals (
100 Colvin Woods Parkway
 
#300
, Tonawanda, New York
) will supply the 
m
inocycline hydrochloride capsules for oral administration contain
ing
 
100 
mg of minocycline 
(NDC number 
00591
-
5695
-
50
, manufactured by 
Actavis
 
Pharma
, Inc.
). 
Pine Pharmaceuticals will 
provide the pink opaque capsules to the NIH Pharmacy.
 
4.7.2
 
Minocycline Formulation
 
for BRC
 
Sites
 
At 
the BRC
 
sites
, minocycline 
hydrochloride capsules for oral administration containing the 
equivalent of 100
 
mg of minocycline will be investigated under European Clinical Trials Database 
(pending EudraCT submission to M.H.R.A.) For the BRC
 
sites
, 
the commercial
 
licensed tablets
 
will 
be overen
capsulated by the BEH pharmacy
.
 
4.7.3
 
Placebo Formulation
 
at 
Pine Pharmaceuticals
 
Pine Pharmaceuticals will 
formulate 
and supply 
a placebo pill with inactive
 
ingredients in a pink 
opaque capsule. 
The prepared capsules will be provided to the NIH Pharmac
y. 
The placebo 
capsules are indistinguishable from the minocycli
ne capsules used in this trial.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
24
 
4.7.4
 
Placebo Formulation for BRC
 
Sites
 
The 
BEH
 
pharmacy has formulated a placebo capsule with inactive ingredients. The placebo 
capsules are 
indistinguishable from the minocycline capsules used in this trial.
 
4.7.5
 
Dosage, Administration
 
and Storage
 
Participants will be instructed to take the 
IP
 
orally two times a day, once in the morning and once in 
the evening approximately 12 hours apart. The exce
ption to this will occur on the day of the baseline 
visit
. On the day of the baseline visit at which IP is dispensed
, participants will take only the evening 
pill. Minocycline will be administered at an oral dose of 100 mg twice daily. Placebo pills contai
n 
no active ingredients.
 
At the baseline and Months 1
-
23 study visits, a 37
-
day supply will be dispensed. 
Participants will 
be given a pill diary upon which to record the morning and evening doses of the 
IP
. The 
IP
 
should 
be stored 
at 15 
–
 
30° C (59 
-
 
86° 
F). It should be protected from light, moisture and excessive heat. 
Participants will be required to return their bottles of 
IP
 
to each visit for pill co
unts for compliance 
monitoring.
 
4.7.6
 
Concomitant Therapy
 
If the study eye develops 
neovascularization warranting panretinal photocoagulation, the 
participant will withdraw from this study because it is known that panretinal photocoagulation 
laser can exacerbate macular edema. This could interfere with the interpretation of the study data
 
(see exc
lusion criteria Section 3.2.2).
 
The non
-
study eye will receive standard care treatment, as appropriate.
 
4.8
 
Investigational Product
 
Accountability
 
The 
p
harmacy 
and/or unmasked 
site 
staff designated to receive 
IP
 
are
 
responsible for the 
accountability of all used and unused study 
IP
. 
Adequate drug accountability records include 
documentation of all 
IP
 
and supplies shipped, received, formulated, dispensed and returned to the 
pharmacy. Participants will be asked to comp
lete a pill diary documenting that they took the 
IP
. 
At each visit, participants will be responsible for the return of a completed pill diary and any 
unused study medication and supplies. The investigator/study staff will review the pill diary with 
the par
ticipant for completeness and accuracy, document the number of returned pills and return 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
25
 
the unused study medication and supplies to 
the 
appropriate p
harmacy.
 
Each
 
pharmacy will 
destroy unused 
IP
 
and supplies following reconciliation by the 
C
oordinating 
C
e
nter
.
 
4.9
 
Follow
-
up/Termination Procedures
 
At the conclusion of the study, the participants will no longer be able to receive the 
IP
 
under this 
protocol.
 
At the NEI, f
ollow
-
up care will be arranged with an outside ophthalmologist or the participant will 
contin
ue to be seen at the NIH under another protocol, if available, and if the participant is eligible. 
The participants and their physicians, with written consent, will be informed of their disease status 
during this study. Clinical data obtained during partic
ipation may be shared with the participants 
and, with written permission from the participants, their private physicians. Results from the 
overall study 
will be listed on 
http://www.clinicaltrials.gov
 
once the 
data have been analyzed
.
 
4.10
 
Storage of Samples and Data
 
No samples will be stored for this study. 
At the NEI, t
he 
clinical data will be stored in the NEI’s 
electronic medical record 
system
 
(EMR)
,
 
The 
Emmes
 
Corporation’s database
 
and the Clinical 
Research Info
rmation System (CRIS)
. 
At the BRC
 
sites
, the clinical data will be stored in 
T
he 
Emmes Corporation’s database. 
Some of the baseline data 
for the NEI 
may be obtained under the 
NEI screening or evaluation and treatment protocols.
 
5.0
 
R
ISKS
/D
ISCOMFORTS
 
There are risks associated with the procedures required for participants in this study. 
 
However, these are all standard procedures that are performed as part of a normal eye and medical 
examination. Some of the discomforts associated wit
h the ocular examination include the 
following:
 
1.
 
Dilating drops or anesthetic drops may sting. They can cause an allergic reaction, or if 
contaminated, can cause an infection, but neither of these problems is very likely to occur. 
Dilating drops can also ca
use a sudden increase of pressure (acute glaucoma) in eyes that 
are already predisposed to develop this condition. There is little risk of glaucoma being 
triggered in this way, but if it is, treatment is available. The participant’s intraocular 
pressure wi
ll be obtained at each ophthalmic examination to determine whether there is an 
increased risk of developing glaucoma.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
26
 
2.
 
Color fundus photographs involve a bright flash to take pictures of the retina. This brief 
flash may cause temporary 
discomfort, but it does not damage the eye.
 
3.
 
In rare instances, the cornea may be scratched during measurement of intraocular pressure 
or use of a funduscopic contact lens. A corneal abrasion of this sort may be painful, but it 
heals quickly with no lasting
 
effects.
 
4.
 
The fluorescein dye used in fluorescein angiography can make a participant’s skin turn 
yellow for several hours. This yellow color is transient and usually disappears in one day. 
Because the dye undergoes renal excretion, the participant’s urine 
will turn dark orange for 
up to 24 hours after the examination. The study team will educate the participant regarding 
this urine color change. Some participants may be slightly nauseated during the 
examination, but their nausea usually lasts only a few sec
onds. If the dye extravasates 
during the injection, the skin around the injection site may feel mildly uncomfortable or 
become yellow. The discomfort usually lasts only a few minutes, and the yellow color fades 
in a few days. There is a chance of ecchymosi
s at the site of injection and a remote 
possibility of ce
llulitis from the needle track.
 
In rare cases, participants may have an allergic reaction to the dye. Treatment typically 
consists of an oral antihistamine medication, but may require intravenous ant
ihistamine 
administration if the symptoms are severe. Very rarely (less than one in one million 
people), a participant experiences anaphylaxis. This would be treated immediately by 
trained personnel with medications or, if necessary, intubation.
 
5.
 
OCT and mi
croperimetry are non
-
invasive tests used to document and analyze retinal 
pathology. Neither test has any known medical risks.
 
Possible discomforts associated with non
-
ocular examinations include:
 
1.
 
Blood draws can cause discomfort and bleeding/bruising at th
e site of venous puncture. 
There is a remote risk of fainting or local infection. If any of these conditions arise, they 
will be treated.
 
2.
 
The medical/ophthalmic history, vital signs, review of systems and pregnancy testing entail 
no medical risk.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
27
 
5.1
 
Intravitr
eal Bevacizumab Risks
 
The following data on the complications of intravitreal injections of bevacizumab were taken from 
a publication on the subject.
43
 
The following event rates were observed as described in Table 1. 
There is no statistically significant difference in event rates between bevacizumab and ranibizumab 
in any of these categories listed
 
below. Risks related to the mechanical injection include 
endophthalmitis, retinal tears, vitreous hemorrhage, intraocular pressure elevation and lens 
damage. Risks related to the pharmacological agent inclu
de uveitis and endophthalmitis.
 
Table 1.
 
Comparison of Ocular Adverse Events Occurred Among Patients Treated 
with
 
Intravitreal Bevacizumab versus Ranibizumab
 
Ocular Adverse Event
 
Bevacizumab 
 
(n = 1,275)
 
(%)
 
Ranibizumab
 
(n = 725)
 
(%)
 
P
 
Retinal detachment 
 
1 (0.08)
 
0
 
1.0
 
Injection
-
site redness
 
821 (64.39)
 
474 (65.38)
 
>0.6
 
Corneal abrasion
 
6 (0.47)
 
3 (0.41)
 
1.0
 
Anterior uveitis
 
20 (1.57)
 
10 (1.38)
 
>0.6
 
Posterior or anterior
-
posterior 
uveitis
 
5 (0.39)
 
3 (0.41)
 
1.0
 
Subconjuctival hemorrhage
 
125 (9.80)
 
75 (10.35)
 
>0.6
 
Subconjuctival hemorrhage 
 
(> 1 quadrant)
 
6 (0.47)
 
5 (0.69)
 
>0.5
 
 
5.2
 
Investigational Product Risks
 
5.2.1
 
Minocycline
-
related
 
Due to oral minocycline’s virtually complete absorption, side effects to the lower bowel, 
particularly diarrhea, have been 
infrequent. The following adverse reactions have been observed 
in patients receiving tetracyclines.
 
Gastrointestinal: 
Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, 
pancreatitis, inflammatory lesions (with monilial over 
growth) in anogenital region and increases 
in liver enzymes. Rarely, hepatitis and liver failure have been reported. Rare instances of 
esophagitis and esophageal ulcerations have been reported in patients taking the tetracycline
-
class 
antibiotics in capsul
e and tablet form. Most of these patients took the medication immediately 
before going to bed.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
28
 
Skin: 
Maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is 
uncommon. Fixed drug eruptions, including balanitis, have been rarel
y reported. 
 
Erythema multiforme and rarely Stevens
-
Johnson syndrome have been reported. 
 
Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some 
individuals taking tetracyclines. This has been reported with minocycline. Pi
gmentation of the skin 
and mucous membranes has been reported.
 
Renal toxicity: 
Elevations in BUN have been reported and are apparently dose related. While this 
is not a problem in those with normal renal function, in patients with significantly impaired 
fu
nction, higher serum levels of tetracycline may lead to azotemia, hyperphosphatemia and 
acidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive 
systemic accumulations of the dr
ug and possible liver toxicity.
 
Hypersensitivity reactions: 
Urticaria, angioneurotic edema, polyarthralgia, anaphylaxis, 
anaphylactoid purpura, pericarditis, exacerbation of systemic lupus erythematosus and rarely 
pulmonary infiltrates with eosinophilia have been reported. A transient lu
pus
-
like syndrome has 
also been reported.
 
Blood: 
Hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia have been reported.
 
Central Nervous System: 
Central nervous side effects including light
-
headedness, dizziness, or 
vertigo have been reported 
with minocycline therapy. Serious neurologic events reported include 
b
ulging fontanels in infants and benign intracranial hypertension (Pseudotumor cerebri) in adults. 
Headache and blurred vision have also been reported.
 
Other: 
When given over prolonged pe
riods, tetracyclines have been reported to produce 
 
brown
-
black microscopic discoloration of the thyroid glands. Very rare cases of abnormal thyroid 
function have been reported. Thyroid cancer has been reported in the post
-
marketing setting in 
association 
with minocycline products. Decreased hearing has been rarely reported in patients on 
minocycline hydrochloride. Tooth discoloration in children less than eight years of age and also, 
rarely, in adults has been reported. Use is not recommended for individua
ls of either gender 
attempting child conception. There is a risk of impaired spermatogenesis. Because tetracycline can 
reduce the amount of beneficial forms of bacteria in the body, participants will be counseled to 
include probiotics in their diet while p
articipating in the study.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
29
 
Pregnant and Nursing Women: 
Minocycline is in Pregnancy Category D and is excreted in human 
milk. Minocycline can cause fetal harm when administered to a pregnant woman. The use of drugs 
of the tetracycline class during tooth dev
elopment (last half of pregnancy, infancy and childhood 
to the age of eight years) may cause permanent discoloration of
 
the teeth (yellow
-
grey
-
brown).
 
5.2.2
 
Drug Interaction
-
related
 
Because tetracyclines have been shown to depress plasma prothrombin activity, pa
rticipants who 
are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to 
avoid giving tetracycline
-
class drugs in conj
unction with penicillin. Absorption of tetracyclines is 
impaired by antacids containing aluminum, calcium, or magnesium, and preparations that contain 
iron. The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal 
renal to
xicity. Concurrent use of tetracyclines with oral contraceptives may render oral 
contraceptives less effective.
 
5.2.3
 
Placebo
-
related
 
There are no medical risks associated with the placebo capsules.
 
6.0
 
Participant Monitoring
 
Participants will be monitored during al
l study visits for 
AE
s by the study investigators. At each 
visit, the participant will be asked about any new ocular or systemic symptoms including rashes, 
hospitalizations or new/changed medications. General and ophthalmic assessments will be 
performed ac
cording to Appendix 2. Stopping guidelines for individual participants and the entire 
study are outlined below.
 
6.1
 
Individual Withdrawal Criteria
 
Participants may choose to withdraw from this study for any reason at any time without penalty, 
without loss of b
enefits, and without prohibition from enrolling in other clinical protocols. 
Participants may stop the study at any time. The investigators will ask all study participants to 
continue to return for study visits even if they stop using the 
IP
. However, part
icipants are free to 
withdraw from the study at any time. Also, investigators may withdraw a participant from 
IP
 
if the 
investigator determines that the study is not in the participant’s best interest.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
30
 
Reasons for participant discontinuation may include, b
ut are not limited to, the following:
 

 
Investigator determination that it is not in the best medical interest of the participant to 
continue participation;
 

 
Findings during the course of the trial that may affect willingness to participate;
 

 
Participant requires additional medicines or intravitreal injections that may interfere with 
the 
IP
;
 

 
Serious suspected adverse reaction;
 

 
VA loss of 

 
15 letters from baseline;
 

 
Any other safety concerns;
 

 
Inability to keep study visits or to comply with stud
y requirements; or
 

 
Participant re
quires ocular surgery which can
not safely be postponed until the end of the 
study.
 
Discontinuation of 
IP
 
does not require participant withdrawal from the study. If the participant 
agrees to continue in the study after disco
ntinuing 
IP
, s/he will continue to return for his/her 
subsequent study visits and undergo the required examinations. Otherwise, the participant will exit 
the study and continue his/her ophthalmic care either with an outside ophthalmologist or at the 
NEI. P
articipants will be monitored by study investigators and clinical staff at each visit to the 
clinic.
 
6.2
 
Pregnancy Monitoring
 
If the staff becomes aware that a female study participant has become pregnant during the study, 
the investigator will advise the part
icipant to stop taking the 
IP
 
immediately. The investigator 
and participant will determine whether to continue any remaining study visits or to exit the study
.
 
If the staff becomes aware that a male study participant has impregnated his partner 
during the 
study, the investigator will remind the participant of the potential r
isks to the unborn fetus.
 
For the NEI site, i
n either case of reported pregnancy, the 
NEI 
participant (and/or partner) will 
be referred to the NIH OB/GYN consultation service 
for evaluation and counseling. 
 
The investigator must follow the participant (or partner) until the pregnancy outcome. The data 
must be recorded on the 
Confirmed Pregnancy 
&
 
Outcome
 
case report 
form, which is also 
reported to the 
C
oordinating 
C
enter
.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
31
 
7.0
 
O
UTCO
ME 
M
EASURES
 
7.1
 
Primary Outcome
 
The primary outcome is the difference in mean change of BCVA, as measured in ETDRS letters, 
between the minocycline and placebo groups 
in the study eye 
at 12 months compared to baseline.
 
7.2
 
Secondary Outcomes
 
Secondary outcomes include the difference between the minocycline and placebo groups in
 
the:
 

 
Number of bevacizumab injections from baseline to 12 months a
nd from baseline to
 
24 months,
 

 
Changes in mean macular sensitivity as measured by microperimetry at 3,
 
6, 12, 18 and 24 
months compared to baseline,
 

 
Mean change in the ETDRS BCVA 
in the study eye 
at 
24 months compared to baseline,
 

 
Changes in retinal thickness as measured by OCT at 6, 12, 18 and 
24 months compared to 
baseline,
 

 
Number of participants improvi
ng 
>
 
1 logOCT scale step at 12 and 24 months compared 
to baseline,
 

 
Changes in fluid leakage in the macula as demonstrated by fluorescein angiography at 
 
12 and 24 months compared to baseline.
 
Also, a decrease of 
≥ 1
-
step on the logOCT scale, where Change i
n logOCT = log
 
(follow
-
up 
thickness/300) 
–
 
log(baseline thickness/300) is considered clinically significant.
42
 
A
 
one
-
step 
decrease is equivalent to at least a 20% improvement of central macular thickness and represents 
greater than twice the variability of
 
retinal thickness measurements (approximately 25
-
30 
microns). Table 2 presents examples of OCT measurements with their corresponding LogSco
re, 
where LogScore = 10xlogOCT.
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
32
 
Table 2. OCT and Corresponding LogScores
42
 
LogScore
 
OCT (µm)
 
0
 
300
 
0.5
 
337
 
1
 
378
 
1.5
 
424
 
2
 
475
 
2.5
 
533
 
3
 
599
 
3.5
 
672
 
4
 
754
 
4.5
 
846
 
5
 
949
 
5.5
 
1064
 
6
 
1194
 
6.5
 
1340
 
7.3
 
Safety Outcomes
 
Safety outcomes will be the number and severity of systemic and ocular toxicities and 
AE
s. 
 
The number of participants withdrawn from the study therapy due to vision loss or 
AE
s 
and the 
number of participants deemed to have worsening disease 
will also cont
ribu
te to the assessment of 
safety.
 
8.0
 
S
TATISTICAL 
A
NALYSIS
 
As this is a pilot study, analyses will be primarily descriptive and by eye. 
Additionally, all 
exploratory analyses carried out may be stratified by site.
 
No formal sample size calculation has 
been p
erformed. The accrual ceiling for this study is 20 participants (10 per group) with a minimum 
of 10 participants (five per group). This number was selected to obtain at least five participants in 
each group reaching the final study visit in order to obtain
 
preliminary data to potentially support 
a larger trial if promising results are revealed.
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
33
 
BCVA will be evaluated at each scheduled visit, and the primary outcome is defined as the 
difference between groups (those randomized to placebo and those randomiz
ed to minocycline) in 
mean change in BCVA in the study eye at 12 months compared to baseline. This study will be 
unable to determine whether there is a statistically significant difference in mean change in BCVA 
between placebo and minoycline groups.
 
Difference in mean change (± standard deviation) in 
BCVA across the two groups will be presented, and interval estimates of mean change in BCVA 
will also be constructed. Exploratory nonparametric statistical analyses will be conducted where 
appropriate. Me
an (per group) and individual BCVA will be plotted against time.
 
The number of bevacizumab injections required by participants will be assessed as a secondary 
outcome. The number of bevacizumab injections will be 
summarized
 
for each participant from 
baseli
ne to 12 months and from baseline to 24 months in each group (those randomized to 
minocycline versus placebo) and the means will be 
compared.
 
Changes in mean macular sensitivity as measured by microperimetry will also be assessed as a 
secondary 
outcome at months 3, 6, 12, 18 and 24 as compared to baseline. A number of recent 
publications have demonstrated the usefulness of microperimetry in assessing macular function in 
vein occlusions.
44
-
55
 
In addition, some of these studies have found that retinal sensitivity as 
measured by microperimetry correlates more precisely with macular edema thickness 
measurements than with visual acuity measurements.
51
-
52
 
Additional secondary outcome measures include changes in retinal thickness in the study eye as 
measured by OCT. Individual and mean changes in retina
l thickness will be 
summarized
 
and 
plotted against time. Other secondary outcomes include change 
in BCVA in the study eye at 12 
and 24 months compared with baseline, 
proportion of participants improving 
≥ 1 logOCT scale 
step, and 
change in fluid leakage in
 
the macula of the study eye as demonstrated by fluorescein 
angiography at 12 and 24 months compared to baseline. In general, changes in BCVA, changes in 
retinal thickness, and changes in fluid leakage in the macula will be monitored throughout the 
study p
eriod in both the study and fellow eyes. Analyses pertaining to these outcomes will be 
descriptive and will include tabulations with point and interval estimates and plots of outcome 
values over the study period for all participants. Exploratory nonparamet
ric statistical analyses will 
be conducted where appropriate.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
34
 
Participants who were exposed to recent (< 
three
 
months) systemic steroid or systemic 
 
anti
-
VEGF prior to enrolling will also be analyzed separately to assess for any possible 
confounding effect
s for treatment benefit.
 
Safety outcomes, including the number and severity of 
systemic and ocular toxicities and 
AE
s will be 
summarized
 
by severity, type and assessed 
relatedness to the 
IP
 
throughout the study period. The number of participants withdrawn 
from the 
IP
 
due to vision loss or 
AE
s and the number of participants deemed to have worsening disease will 
also be 
summarized
. Worsening disease is defined as loss of 15 or more ETDRS letters of vision 
compared to baseline OR a 
≥ 1
-
step increase in the log
OCT scale. These safety analyses will use 
data of all participants who were exposed to 
IP
 
regardless of adherence to the protocol.
 
Participants’ compliance with IP administration will be assessed through capsule counts during 
study visits. If study IP comp
liance falls below 80% of the level prescribed for any participant, the 
participant will be queried 
by the site 
about the reasons for decreased compliance and counseled 
on the importance of compliance for study integrity. The level of compliance will be re
ported to 
the IRB on annual review and taken into account in the analyses of study outcomes
.
 
When 
IP 
compliance cannot be determined for a participant during any visit due to missing capsule counts, 
IP compliance will be imputed by taking the median of 
all available capsule counts recorded at 
previous study visits.
 
9.0
 
H
UMAN 
P
ARTICIPANTS 
P
ROTECTION
 
9.1
 
Equitability
 
Accrual for this study will be equitable among participants with RVOs meeting the enrollment 
criteria. All participants will have received the st
andard care therapy prior to enrollment.
 
9.1.1
 
Justification for Exclusion of Children
 
Children are not eligible for this study as minocycline has not been fully studied in children and is 
not indicated for use in children.
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
35
 
9.1.2
 
Justification for Exclus
ion of Pregnant or Lactating Women
 
Pregnant or lactating women are not eligible for 
this study because of the known and unknown 
risks of minocycline. 
One of the known risks of minocycline is that it can cause permanent 
discoloration of the teeth (yellow
-
gr
ey
-
brown) of a fetus when given to a pregnant woman during 
the last half of pregnancy. Minocycline also passes into breast milk and can cause permanent 
discoloration of the teeth of a nursing infant. 
Given the known and unknown effects on pregnancy 
outcome
s, two forms 
(one form for BRC sites) 
of contraception will be required for female 
participants of childbearing potential (see Appendix 1 for definition). In addition, female 
participants of childbearing potential will undergo urine pregna
ncy tests through
out the study.
 
9.2
 
Qualifications of Investigators
 
The following physicians who will be treating the participants are experienced in caring for 
patients with RVOs. In addition, they are experienced in conducting st
udies similar to this protocol.
 
Credential
ed NEI staff physicians may also conduct procedures under the direction of these 
investigators.
 
The 
NEI 
PI
 
has verified that all individuals working on this protocol 
at the NEI site 
required to 
take HRPP training under OHSRP SOP 25 (Training 
requirements for the NIH Human Research 
Protections Program) have completed all required training.
 
The 
BRC site
 
PIs have verified that all individuals working on this protocol at thei
r s
ite are 
sufficiently trained to complete the tasks delegated to them o
n the study Authorized Staff Signature 
log
.
 
Catherine Cukras, MD, PhD is the 
PI
 
with the ability to obtain informed consent. She is responsible 
for obtaining medical history, performing scheduled ophthalmic study visits, 
dispensing/administering medication
, maintaining regulatory documentation, submitting IRB 
materials, generating clinical source documents, resolving data queries and overseeing the 
protocol.
 
Dr. Cukras is currently a staff clinician at NEI. She completed the medical retina clinical 
fellowsh
ip at NEI and has mentored medical students in the NEI retina clinic. Dr. Cukras currently 
serves as the 
PI
 
on a protocol investigating minocycline for the treatment of macular edema. 
 
She has also served as an Associate Investigator on other clinical rese
arch stud
ies on related ocular 
diseases.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
36
 
Clare Bailey, MD is the 
PI
 
for the Bristol Eye Hospital with the ability to obtain informed consent
 
at the UK sites
. She is responsible for obtaining medical history, performing scheduled ophthalmic 
study 
visits, administering and dispensing medication, completing regulatory documentation and 
regulatory submissions, generating clinical source documents, resolving data queries and the 
overall oversight of the protocol for the BEH site.
 
Dr.
 
Bailey is a consul
tant ophthalmologist in 
medical and surgical retina at the BEH and a member of the Royal College of Ophthalmologists
.
 
Bishwanath Pal
, 
MBBS, MS, Ophth,
 
FRCOphth, FRCSEdin
, is the PI for Moorfields Eye Hospital 
with the ability to obtain informed consent fro
m patients
 
at the MEH site
.
 
He is responsible for 
obtaining medical history, performing scheduled ophthalmic study visits, administering and 
dispensing medication, completing, generating clinical source documents, resolving data queries 
and the overall ove
rsight of the protocol for the
 
Moorfields site.
 
Dr.
 
Pal is a consultant 
ophthalmologist in medical retina at Moorfields Eye Hospital and a member of the Royal College 
of Ophthalmologists.
 
Wai Wong, MD, PhD is the Lead Associate Investigator with the abilit
y to obtain informed 
consent. He is responsible for obtaining medical history, performing scheduled ophthalmic study 
visits, dispensing/administering medication and generating clinical source documents. Dr. Wong 
is a staff clinician and the head of the uni
t of neuron
-
glial interactions in retinal diseases at NEI. 
Dr. Wong currently serves as an Associate Investigator on another protocol for the treatment of 
macular edema targeting microglia. Dr. Wong has clinical experience and conducted research 
studies on
 
related ocular diseases as a Principal and Associate Investigator.
 
Emily Chew, MD is an Associate Investigator and Accountable Investigator with the ability to 
obtain informed consent. She is responsible for obtaining medical history, performing scheduled
 
ophthalmic study visits, dispensing/administering medication and generating clinical source 
documents. Dr. Chew is the deputy clinical director
 
(CD)
 
and director of the medical retina 
fellowship program at NEI. Dr. Chew is on the editorial board of a diab
etic journal and serves on 
several committees focused on the care of patients with diabetes. Dr. Chew has conducted 
numerous research studies as a Principal and Associate Investigator on related ocular diseases.
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
37
 
Henry Wiley, MD is an Associate Investigat
or with the ability to obtain informed consent. He is 
responsible for obtaining medical history, performing scheduled ophthalmic study visits, 
dispensing/administering medication and generating clinical source documents. Dr. Wiley has 
clinical experience a
nd has conducted research studies as a Principal and Associate Investigator 
on related ocular diseases.
 
Alexander Kaplan, MD, Christopher Hwang, MD and Munir Iqbal, MD, FRCSC
 
are 
Associate 
Investigator
s
 
with the ability to obtain informed consent. 
They
 
are
 
responsible for obtaining 
medical history, performing scheduled ophthalmic study visits, dispensing/administering 
medication and generating clinical source documents. 
They are
 
currently clinical fellow
s
 
at the 
NEI.
 
Angela Kibiy, MPH,
 
BSN, RN 
is 
an Associa
te Investigator and
 
the Research Contact 
with
out
 
the 
ability to obtain informed consent
. She is responsible for providing assistance to the 
PI
 
with study 
procedures, generating clinical source documents, entering dat
a and resolving data queries. 
 
Ms. 
Kibiy
 
has been involved in clinical research studies on ocular diseases as an Associate 
Investigator and primary study coordinator/research contact
.
 
Awilda V.
 
Holland, DNP, MSHSc, RN, CCRP is 
an Associate Investigator and back
-
up 
coordinator
 
without the ability to obtain informed consent. She is responsible for providing 
assistance to the 
PI
 
with study procedures, generating clinical source documents
, entering data and 
resolving data queries. 
Dr
. Holland is the NEI Clinical Trials Coordinating Section Chief and has 
been involved in clinical research studies on ocular diseases
.
 
Prior to screening or enrolling potential participants, the 
PI
 
will verify 
all individuals working on 
this protocol have met the following training and certification requirements as applicable to their 
indicated role:
 
9.2.1
 
Professional Licensure
 
Physicians must provide evidence of current medical licensure applicable to the stud
y location(s) 
if they are practicing medicine and undertake to diagnose and/or treat participants (including 
administration of the 
IP
) in this study. A physician who is a site 
PI
 
must also provide satisfactory 
evidence of ophthalmology training before stud
y initiation
.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
38
 
10.0
 
A
NTICIPATED 
B
ENEFITS
 
During this study, all participants will be eligible to receive intravitreal bevacizumab (Avastin
®

, 
an anti
-
VEGF agent. Additionally, participants who are randomized to minocycline may benefit 
directly from this study, as we hypothesize that minocycline may result in resolution or reduction 
of macular edema or improved visual acuity or need for fewer i
ntravitreal bevacizumab injections. 
The study will also lead to generalizable knowledge 
regarding 
macular edema associated with 
CRVO.
 
11.0
 
C
LASSIFICATION OF 
R
ISK
 
Risk is classified as 
more than minimal risk
. The risks will be minimized with careful 
monitoring and 
are reasonable given that the participants are experi
encing visual loss due to CRVO.
 
12.0
 
C
ONSENT 
D
OCUMENTS AND 
P
ROCESS
 
Applicable study investigators with consenting privileges will obtain informed consent. 
All NIH 
study investigators obtaining 
informed consent have completed the National Institute of Mental 
Health (NIMH) Human Subject’s Protection Unit (HSPU) “Elements of Successful Informed 
Consent” training. 
All participants will receive a verbal explanation in terms suited to their 
comprehens
ion of the purposes, procedures and potential risks of the study. The participants must 
have the ability to understand and sign an informed consent form, which must be signed prior to 
enrollment. The participants will have an opportunity to carefully revie
w the consent and ask 
questions regarding this study prior to signing and they will be informed that they may withdraw 
from the study at any time without penalty to themselves or benefits lost.
 
If the participant requires the consent to be in larger font i
n order to read it well, this will be 
provided. If participants are visually impaired to the point of being unable to read the consent, they 
can take the consent back with them to read it over with a family member or with the use of 
magnifying devices. If 
the participant chooses, the investigator can also read the consent verbatim 
to the participant and answe
r any questions that may arise.
 
An
 
investigator 
present during the
 
consent 
process 
will document the consent process in the 
participant’s medical recor
d. A signed copy of the informed consent form will be provided to the 
participant to take home.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
39
 
12.1
 
Unanticipated Enrollment of 
Non
-
English Speaking Participants
 
at the NEI
 
If a non
-
English speaking participant is eligible for enrollment
 
at the 
NIH
 
Clinic
al Center (CC)
, 
the participant will be provided with the 
CC Short Written Consent Form for Non
-
English 
Speaking Research Subjects
 
in the participant’s native language and a verbal explanation of the 
purpose, procedures and risks of the study. The IRB
-
appr
oved English consent form will serve as 
basis for the verbal explanation of the study. The investigator will obtain an interpreter unless the 
investigator is fluent in the prospective participant’s language. Preferably, the interpreter will be 
someone who 
is 
not related to
 
the participant (i.e., not a family member). Interpreters provided by 
the CC will be used whenever possible. The interpreters will 
interpret
 
the IRB
-
approved English 
consent form and facilitate discussion between the participant and inves
tigator.
 
The IRB
-
approved English consent form will be signed by the investigator obtaining consent and 
a witness to the oral presentation. The CC Short Written Consent Form will be signed by the 
participant and a witness who observed the presentation of i
nformation. The interpreter may sign 
the consent document as the witness and, in this case, will note “Interpreter” 
with his/her
 
signature. 
If not also serving as the witness, the interpreter will be separately identified on the short form in 
the space pro
vided.
 
A copy of both signed forms 
(the long form serving as the script and the short 
form)
 
will be provided to the participant.
 
The short form process, including the use of an 
interpreter, will be documented in the medical record in accordance with NIH 
policy.
 
A
ll instances of use of the CC Short Written Consent Form will be reported to the IRB at the time 
of annual review. If the CC Short Written Consent Form is used three times or more for the same 
language within an IRB approval period, this will be r
eported to the IRB immediately.
 
Interpreters will also be present for other protocol procedures as necessary.
 
13.0
 
D
ATA AND 
S
AFETY 
M
ONITORING
 
The NEI Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data and 
safety, and will exercise ov
ersight of the clinical investigation independently from the study 
investigators.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
40
 
13.1
 
Coordinating Center
 
The 
Emmes
 
Corporation has been assigned as the coordinating center for this trial to conduct data 
collection, protocol monitoring, data analysis and 
reporting. The coordinating center provides 
routine monitoring of study participants’ data. Monitoring visits will occur on a schedule 
depending on the status of the study. More frequent monitoring visits will be performed at the 
beginning of the study whe
n enrollment is open. Monitoring will decrease as enrollment closes 
and as participant follow
-
up continues. The protocol monitor will monitor documentation for the 
informed consent process. In addition, the protocol monitor will review source documentation
 
for 
the data collected throughout the trial to ensure that the data points are collected and reported.
 
Communications between the investigational site and the Coordinating Center will be maintained 
through regular telephone and e
-
mail contacts between the
 
Coordinating Center Protocol Monitor 
and the site 
PI
 
and/or Coordinator. Substantive communications must be maintained both at the 
site and at the Coordinating Center containing the date and a summary of communications where 
instructions are given or rece
ived, an interpretation of protocol requirements is made, 
recommendations for corrections to study documentation are made, or where the reporting of 
possible 
AE
s is discussed
.
 
Although the 
C
oordinating 
C
enter 
advises the NEI 
CD
 
and 
PI
 
on data and statistic
al activities, the 
C
oordinating 
C
enter 
staff does not have direct access to or interaction with participants.
 
13.2
 
Data and Safety Monitoring Committee
 
The NEI DSMC is responsible for reviewing and approving the study design and, as appropriate, 
recommending design changes. In addition, the DSMC assesses study data with particular 
consideration of participant safety. The DSMC will convene prior to the ini
tiation of the trial to 
review the protocol. 
Emmes will provide accumulated data from all study sites to the NEI DSMC 
for review. 
The Committee will review accumulated data on a 
biannual 
basis, but will convene ad 
hoc meetings to address any significant pr
oblems related to participant safety brought to its 
attention by any study participant or investigator. The Committee will review the accumulated data 
and consider whether a protocol modification is necessary and approve protocol modifications. 
 
If 
changes in protocol are indicated, recommendations will be made to the NEI Director and 
Clinical Center Director who will consider and act on such recommendations in a timely manner.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
41
 
All protocol amendments must be reviewed and approved by the NEI DSMC pri
or to submission 
to the IRB.
 
13.3
 
Criteria for Stopping the Study
 
The DSMC may recommend temporarily suspending or closing enrollment, or stopping the study 
at any time due to safety concerns, demonstration of efficacy or lack of efficacy, or slow 
recruitm
ent. Criteria for stopping the study include the following:
 

 
A sufficiently large number of dropouts occurs as to make the trial likely to be 
uninformative;
 

 
A participant experiences a drop in BCVA in the study eye of 

 
30 letters from baseline 
attributed t
o the 
IP
;
 

 
A participant experiences a serious adverse event
 
(SAE)
, drug reaction or complication, 
whether attributed to the 
IP
 
or not, which has an impact on visual function or any other 
body system or precludes continuation of the 
IP
. This would include t
he development of 
hypersensitization, allergic responses or other potentially serious drug reactions to 
medications required by the protocol.
 
Following premature 
IP
 
discontinuation, not due to an 
AE
, participants will continue to be 
followed as per the pro
tocol.
 
14.0
 
Q
UALITY 
A
SSURANCE
 
The NEI and Emmes maintain quality control by adhering to standard operating procedures 
 
(NEI QA program and NEIS standard operating procedures). These procedures cover the full 
protocol cycle beginning with staff credentialing and
 
training, and protocol development and 
approval, through database development, data collection, monitoring and analysis, and finally 
manuscript preparation at the conclusion of the study. Data quality assurance is of the utmost 
importance to the NEI and E
mmes. The two groups use a quality assurance system that relies on 
real
-
time data checks and reports throughout the course of a study to ensure the accuracy of 
information. This system is a secure and confidential data management system that stores data an
d 
provides quality assurance and reporting. Emmes has developed a number of routine reports 
specifically designed for monitors (e.g., listings of 
SAE
s, etc.)
.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
42
 
Additionally, Emmes has developed summary reports of discrepancies, as well as reports of the 
exc
eptions databases, which include requests and reasons for exceptions. The results of the reports 
are communicated back to site staff, and, along with protocol compliance issues, to the DSMC (if 
applicable)
.
 
Following the monitoring plan for this study, Emm
es will perform monitoring activities, including 
on
-
site audits, review of database entries and the resolution of study issues. In addition to 
monitoring, Emmes performs various detailed automated and manual data quality checks. 
 
The results from these che
cks and any protocol compliance issues are communicated back to site 
staff and to the NEI Project Officer, NEI 
CD
 
and applicable regulatory bodies
.
 
15.0
 
R
EPORTING OF 
U
NANTICIPATED 
P
ROBLEMS
,
 
A
DVERSE 
E
VENTS AND 
P
ROTOCOL 
D
EVIATIONS
 
The 
PI
 
is responsible for detect
ing, documenting, and reporting unanticipated problems, 
AE
s, 
including 
SAE
s, and deviations in accordance with NIH policy, IRB requirements, and federal 
regulations. 
For the BRC sites, site PI is responsible for
 
detecting, documenting, and re
porting 
unanticipated problems,
 
AEs, including SAEs, and deviations, occurring at their site. 
 
Relatedness to the research of all 
SAE
s will be determined by the PI in consultation with the CD.
 
Additionally, both the Sponsor and Investigator will report 
AE
s (SAEs/S
USARs) from the sites in 
accordance with the European Directive 2001/20/EC. 
SAE
s must be reported to the Sponsor by 
the Investigators within 24 hours of awareness. Non
-
SAE
s that are expected as part of the natural 
history of the underlying disease will be 
summarized at the time of annual review
 
to the IRB
.
 
Serious unanticipated problems, 
SAE
s (including deaths) that are not unanticipated problems, and 
serious protocol deviations 
at the NIH 
will be reported to the 
CNS 
IRB and CD as soon as possible 
and in wr
iting not more than 
seven 
days after the PI first learns of the event, unless immediate 
reporting is waived for specific 
SAE
s as noted below
. 
Not serious unanticipated problems and not 
serious deviations 
at the NIH 
will be reported to the
 
CNS
 
IRB and CD as
 
soon as possible and in 
writing on the NIH Problem Report Form not more than 14 days after the PI first learns of the 
event.
 
Written reports will be submitted in PTMS.
 
For the BRC sites, the site PI is responsible for 
reporting events, including SAEs and 
protocol deviations to Emmes and the Sponsor
,
 
and then 
further report
ing to regulatory authorities if
 
reporting requirements are met.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
43
 
All u
nanticipated problems, 
SAE
s, and protocol deviations at the B
RC
 
sites 
will be monitored and 
reported per local regula
tions. 
These events will 
be reported to the 
NEI DSMC
 
and 
unanticipated 
problems 
will 
be reported to the CNS IRB 
in the timeframes specified above
.
 
All 
AE
s, deviations, and unanticipated problems will be summarized and reported
 
to the CNS IRB
 
at the time of Continuing Review.
 
16.0
 
A
LTERNATIVE 
T
HERAPIES
 
Alternatives to participation include further repeat treatment with intraocular injections of 
 
anti
-
VEGF agents such as bevacizumab (Avastin
®
) or ranibizumab (Lucentis
®
) without 
randomization to minocycline or placebo. 
Ranibizumab (Lucentis
®
) recently has been 
demonstrated to improve vision and edema, but the durability of the injections remains unknown.
 
Other alternatives include the use of periocular and intraocular co
rticosteroids. Another approach 
would be observation. 
Other therapies have been administered with varying rates of success. 
 
All of these options are associated with significant side effects and complications if the treatment 
is extended and increased.
 
Par
ticipants can alternatively receive minocycline outside of the study 
if prescribed off
-
label by their own physician
.
 
17.0
 
P
RIVACY
 
All research activities will be conducted in as private a setting as possible
.
 
18.0
 
C
ONFIDENTIALITY
 
No blood, tissue or other 
samples will be stored in this study. All medical records will be kept 
confidential and will only be reviewed by the participating investigators. Data will be kept
 
in 
password
-
protected computers held at the NEI and the 
C
oordinating 
C
enter
. Only study 
inve
stigators and authorized 
C
oordinating 
C
enter 
staff will have access to the study data. 
 
The 
participants
’ names will not appear on any of the data forms reported to the 
C
oordinating 
C
enter
. A unique identifier will identify the participant if their informa
tion is shared with the 
C
oordinating 
C
enter 
for research purposes. The 
participants
’ names will not appear in any 
publication of the study results. Participants’ personal information will be kept as private as 
possible. However, records can be inspected by
 
organizations for quality assurance and data 
analysis. Potential inspectors include the members of the FDA, IRB, DSMC and the 
C
oordinating 
C
enter
.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
44
 
19.0
 
C
ONFLICT OF 
I
NTEREST
 
The NIH guidelines were distributed to all the investigators, and none of the investiga
tors had any 
conflicts of interest
.
 
20.0
 
T
ECHNOLOGY 
T
RANSFER
 
There are no technology transfer agreements for this study
.
 
21.0
 
R
ESEARCH AND 
T
RAVEL
 
C
OMPENSATION
 
For this study, there is no compensation for participation. This protocol does not include 
reimbursement fo
r travel and subsistence. Participants needing financial assistance will be able to 
receive supplemental reimbursement based upon need. Requests for supplemental reimbursement 
will be evaluated on a case
-
by
-
case basis for valid financial and/or medical nee
d through a 
standardized process.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
45
 
22.0
 
References
 
1.
 
Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in 
Australia. The Blue Mountains Eye Study. 
Archives of ophthalmology 
1996; 
114
(10)
: 
1243
-
1247.
 
2.
 
Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein oc
clusion: the 
Beaver Dam Eye Study. 
Transactions of the American Ophthalmological Society 
2000; 
98: 
133
-
141; discussion 141
-
133.
 
3.
 
Brown DM, Campochiaro PA, Singh RP
 
et al.
 
Ranibizumab for macular edema following 
central retinal vein occlusion: six
-
month p
rimary end point results of a phase III study. 
Ophthalmology
; 
117
(6)
: 
1124
-
1133 e1121.
 
4.
 
Kaur C, Foulds WS, Ling EA. Blood
-
retinal barrier in hypoxic ischaemic conditions: Basic 
concepts, clinical features and management. 
Progress in retinal and eye resea
rch 
2008.
 
5.
 
Yoshida S, Yoshida A, Ishibashi T. Induction of IL
-
8, MCP
-
1, and bFGF by TNF
-
alpha in 
retinal glial cells: implications for retinal neovascularization during post
-
ischemic 
inflammation. 
Graefe's archive for clinical and experimental ophthalmology = Albrech
t von 
Graefes Archiv fur klinische und experimentelle Ophthalmologie 
2004; 
242
(5)
: 
409
-
413.
 
6.
 
Noma H, Funatsu H, Yamasaki M
 
et al.
 
Pathogenesis of macular edema with branch retinal 
vein occlusion and intraocular levels of vascular endothelial growth facto
r and interleukin
-
6. 
American journal of ophthalmology 
2005; 
140
(2)
: 
256
-
261.
 
7.
 
Bek T. Capillary closure secondary to retinal vein occlusion. A morphological, 
histopathological, and immunohistochemical study. 
Acta ophthalmologica Scandinavica 
1998; 
76
(6)
:
 
643
-
648.
 
8.
 
Antonetti DA, Barber AJ, Bronson SK
 
et al.
 
Diabetic retinopathy: seeing beyond glucose
-
induced microvascular disease. 
Diabetes 
2006; 
55
(9)
: 
2401
-
2411.
 
9.
 
Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein 
Occlusion Study Group. 
American journal of ophthalmology 
1984; 
98
(3)
: 
271
-
282.
 
10.
 
Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein 
occlusion: an evidence
-
based systematic review. 
Ophthalmology 
2007; 
114
(3)
: 
507
-
519, 524.
 
11.
 
Giulian D, Li J, Bartel S, Broker J, Li X, Kirkpatrick JB. Cell surface morphology identifies 
microglia as a distinct class of mononuclear phagocyte. 
J Neurosci 
1995; 
15
(11)
: 
7712
-
7726.
 
12.
 
Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distri
bution and morphology of 
microglia in the normal adult mouse brain. 
Neuroscience 
1990; 
39
(1)
: 
151
-
170.
 
13.
 
Flaris NA, Densmore TL, Molleston MC, Hickey WF. Characterization of microglia and 
macrophages in the central nervous system of rats: definition of t
he differential expression of 
molecules using standard and novel monoclonal antibodies in normal CNS and in four models 
of parenchymal reaction. 
Glia 
1993; 
7
(1)
: 
34
-
40.
 
14.
 
Liu B, Hong JS. Role of microglia in inflammation
-
mediated neurodegenerative diseas
es: 
mechanisms and strategies for therapeutic intervention. 
The Journal of pharmacology and 
experimental therapeutics 
2003; 
304
(1)
: 
1
-
7.
 
15.
 
Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in 
neurological disease, with special reference to AIDS and Alzheimer's disease. 
Glia 
1993; 
7
(1)
: 
75
-
83.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
46
 
16.
 
McMillian MK, Thai L, Hong JS, O'Callaghan JP, Pennypacker KR. Brain in
jury in a dish: a 
model for reactive gliosis. 
Trends Neurosci 
1994; 
17
(4)
: 
138
-
142.
 
17.
 
Zeiss CJ, Johnson EA. Proliferation of microglia, but not photoreceptors, in the outer nuclear 
layer of the rd
-
1 mouse. 
Investigative ophthalmology & visual science 
200
4; 
45
(3)
: 
971
-
976.
 
18.
 
Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late
-
onset 
retinal degeneration, and age
-
related macular degeneration. 
Exp Eye Res 
2003; 
76
(4)
: 
463
-
471.
 
19.
 
Gardner TW, Antonetti DA, Barber AJ, LaNoue 
KF, Levison SW. Diabetic retinopathy: more 
than meets the eye. 
Surv Ophthalmol 
2002; 
47 Suppl 2: 
S253
-
262.
 
20.
 
Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. 
Archives 
of ophthalmology 
2008; 
126
(2)
: 
227
-
232.
 
21.
 
Shin JM, Qua
n FS, Lee JH, Chun MH, Oh SJ. Neural Cell Attitudes in Ischemic Retinas 
Evoked by Ischemia/Reperfusion and by Venous Cauterization. 
Invest Ophthalmol Vis Sci
; 
51
(5)
: 
2243
-
A423.
 
22.
 
Lin CM, Wolpert EB, Shanmugam S, Antonetti DA, Gardner TW, Abcouwer SF. Dif
ferent 
Effects of Minocycline and Doxycycline on Retinal Vascular Permeability and 
Neurodegeneration in Ischemia
-
Reperfusion. 
Invest Ophthalmol Vis Sci
; 
51
(5)
: 
3648
-
A298.
 
23.
 
Lee JE, Liang KJ, Fariss RN, Wong WT. Ex vivo dynamic imaging of retinal microgli
a using 
time
-
lapse confocal microscopy. 
Investigative ophthalmology & visual science 
2008; 
49
(9)
: 
4169
-
4176.
 
24.
 
Zemke D, Majid A. The potential of minocycline for neuroprotection in human neurologic 
disease. 
Clin Neuropharmacol 
2004; 
27
(6)
: 
293
-
298.
 
25.
 
T
ikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline 
derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation 
of microglia. 
J Neurosci 
2001; 
21
(8)
: 
2580
-
2588.
 
26.
 
Ryan ME, Usman A, 
Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix 
metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. 
Curr Med Chem 
2001; 
8
(3)
: 
305
-
316.
 
27.
 
Lampl Y, Boaz M, Gilad R
 
et al.
 
Minocycline treatment in acute
 
stroke: an open
-
label, 
evaluator
-
blinded study. 
Neurology 
2007; 
69
(14)
: 
1404
-
1410.
 
28.
 
Pi R, Li W, Lee NT
 
et al.
 
Minocycline prevents glutamate
-
induced apoptosis of cerebellar 
granule neurons by differential regulation of p38 and Akt pathways. 
Journal of 
neurochemistry 
2004; 
91
(5)
: 
1219
-
1230.
 
29.
 
Shimazawa M, Yamashima T, Agarwal N, Hara H. Neuroprotective effects of minocycline 
against in vitro and in vivo retinal ganglion cell damage. 
Brain research 
2005; 
1053
(1
-
2)
: 
185
-
194.
 
30.
 
Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta 
deposition, and behavior in APP
-
tg mice. 
Glia 
2006; 
53
(7)
: 
776
-
782.
 
31.
 
Kraus RL, Pasieczny R, Lariosa
-
Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant 
prope
rties of minocycline: neuroprotection in an oxidative stress assay and direct radical
-
scavenging activity. 
Journal of neurochemistry 
2005; 
94
(3)
: 
819
-
827.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
47
 
32.
 
Krady JK, Basu A, Allen CM
 
et al.
 
Minocycline reduces proinflammatory cytokine expression, 
microglial activation, and caspase
-
3 activation in a rodent model of diabetic retinopathy. 
Diabetes 
2005; 
54
(5)
: 
1559
-
1565.
 
33.
 
Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho 
J. A tetracycline 
derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia 
with a wide therapeutic window. 
Proceedings of the National Academy of Sciences of the 
United States of America 
1999; 
96
(23)
: 
13496
-
13500.
 
34.
 
Yrja
nheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit 
microglial activation and are neuroprotective in global brain ischemia. 
Proceedings of the 
National Academy of Sciences of the United States of America 
1998; 
95
(26)
: 
15769
-
15
774.
 
35.
 
Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain 
injury
-
mediated caspase
-
1 activation, tissue damage, and neurological dysfunction. 
Neurosurgery 
2001; 
48
(6)
: 
1393
-
1399; discussion 1399
-
1401.
 
36.
 
Festoff BW, Ameen
uddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. Minocycline 
neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal 
cord injury. 
Journal of neurochemistry 
2006; 
97
(5)
: 
1314
-
1326.
 
37.
 
Wells JE, Rice TK, Nuttall 
RK
 
et al.
 
An adverse role for matrix metalloproteinase 12 after 
spinal cord injury in mice. 
J Neurosci 
2003; 
23
(31)
: 
10107
-
10115.
 
38.
 
Bosco A, Inman DM, Steele MR
 
et al.
 
Reduced retina microglial activation and improved optic 
nerve integrity with minocycli
ne treatment in the DBA/2J mouse model of glaucoma. 
Investigative ophthalmology & visual science 
2008; 
49
(4)
: 
1437
-
1446.
 
39.
 
Yang LP, Zhu XA, Tso MO. A possible mechanism of microglia
-
photoreceptor crosstalk. 
Molecular vision 
2007; 
13: 
2048
-
2057.
 
40.
 
Leung
 
DW, Lindlief LA, Laabich A
 
et al.
 
Minocycline protects photoreceptors from light and 
oxidative stress in primary bovine retinal cell culture. 
Investigative ophthalmology & visual 
science 
2007; 
48
(1)
: 
412
-
421.
 
41.
 
Smith K, Leyden JJ. Safety of doxycycline 
and minocycline: a systematic review. 
Clin Ther 
2005; 
27
(9)
: 
1329
-
1342.
 
42.
 
Ferris FL 3rd, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research 
Network. A proposed method of logarithmic transformation of optical coherence tomography 
data
 
for use in clinical research. 
Ophthalmology
 
2010 Aug; 117(8):1512
-
6.
 
43.
 
Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat 
intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 
inject
ions. 
Retina
 
2009; 29(3): 313
-
318.
 
44.
 
Yamaike N, Tsujikawa A, Sakamoto A, et al. Retinal sensitivity after intravitreal injection of 
bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. 
Retina
 
2009; 29: 757
-
767.
 
45.
 
Winterhalter S, Lux A, Maier AK, et al. Microperimetry as a routine diagnostic test in the 
follow
-
up of retinal vein occlusion? Graefes Arch Clin Exp 
Ophthalmol 
2011; 
doi:10.1007/s00417
-
011
-
1784
-
8
 
46.
 
Senturk F, Ozdemir H, Karacorlu
 
M, Karacorlu SA, Uysal O. Microperimetric changes after 
intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein 
occlusion. 
Retina 
2010;
 
30: 1254
-
1261.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
48
 
47.
 
Schneider U, Inhoffen W, Grisanti S, Bartz
-
Schmidt KU. Characte
ristics of visual field defects 
by scanning laser ophthalmoscope microperimetry after radial optic neurotomy for central 
retinal vein occlusion. 
Retina 
2005;
 
25: 704
-
712.
 
48.
 
Schmidt B, Krummenauer F, Losche CC. [Evaluation of Possible Prognostic Factors f
or the 
Course of Visual Acuity after Intravitreal Ttriamconolone Acetonide.]. 
Klin Monbl 
Augenheilkd
 
2011; 229(1), 56
-
61. doi: 10.1055/s
-
0031
-
1281586.
 
49.
 
Ogino K, Tsujikawa A, Murakami T, et al. Evaluation of macular function using focal macular 
electrore
tinography in eyes with macular edema associated with branch retinal vein occlusion. 
Investigative Ophthalmology & Visual Science
 
2011; 52(11): 8047
-
8055. 
 
50.
 
Noma H, Funatsu H, Mimura T, Shimada K. Visual function and serous retinal detachment in 
patient
s with branch retinal vein occlusion and macular edema: a case series. 
BMC
 
Ophthalmol
 
2011; 11, 29.
 
51.
 
Noma H, Funatsu H, Mimura T, Harino S, Shimada K. Functional
-
morphologic correlates in 
patients with branch retinal vein occlusion and macular edema. 
Re
tina
 
2011; 31(10), 2102
-
2108.
 
52.
 
Kriechbaum K, Prager F, Geitzenauer W, et al. Association of retinal sensitivity and 
morphology during antiangiogenic treatment of retinal vein occlusion over one year. 
Ophthalmology
 
2009; 116(12): 2415
-
2421.
 
53.
 
Fujii GY,
 
de Juan E, Jr., Humayun MS. Improvements after sheathotomy for branch retinal 
vein occlusion documented by optical coherence tomography and scanning laser 
ophthalmoscope. 
Ophthalmic Surg Lasers Imaging 
2003; 34(1): 49
-
52.
 
54.
 
Chalam KV, Shah VA. Resolutio
n of macular scotoma after radial optic neurotomy in central 
retinal vein occlusion. 
Ophthalmic Surg Lasers Imaging
 
2006; 37(1): 72
-
75.
 
55.
 
Barbazetto IA, Schmidt
-
Erfurth UM. [Quantification of functional retinal damage in branch 
retinal vein thromboses]. 
Ophthalmologe
 
1999; 96(3): 159
-
165.
 
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
49
 
A
PPENDIX 
1:
 
D
ETERMINING 
C
HILDBEARING 
P
OTENTIAL
 
A female participant who is considered non
-
childbearing due to a medical condition 
 
(i.e., participant has previously undergone a hysterectomy) does not need a 
pregnancy test, 
Follicle
-
stimulating Hormone (FSH) test or contraception.
 
If a female participant is considered non
-
childbearing due to menopause, it must be in accordance 
with the CNS IRB/NIH Ob
-
Gyn guidance on the definition of menopause. This guidance d
efines 
menopause as:
 

 
Women over age 55 who have not had a period for one year will be considered menopausal 
and do not need a pregnancy test, FSH test or contraception.
 

 
Women between 50 and 55, who have not had a period for one year, should have an FSH 
tes
t. If their FSH level is 
≥ 20 mIU/mL, they will be considered menopausal and do not 
need pregnancy testing or contraception. If their FSH level is < 20 mIU/mL, they will need 
pregnancy testing and contraception as required by the protocol.
 

 
Women between 45
 
and 50 who have not had a period for one year will need both an FSH 
test and a pregnancy test. If they are not pregnant and their FSH level is 
≥ 20 mIU/mL, 
they will be considered menopausal and will not require contraception or additional 
pregnancy testi
ng. If their FSH test is < 20 mIU/mL, they will need pregnancy testing and 
contraception as required by the protocol.
 
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
50
 
A
PPENDIX 
2:
 
S
TUDY 
F
LOWSHEET
 
Study Visit Number* (Month)
 
0
 
1
 
2
 
3
-
11
 
12
 
13
-
23
 
24
 
SFTY
13
 
Visit Number
 
 
00
 
01
 
02
 
03
-
11
 
12
 
13
-
23
 
24
 
SFTY
 
Target Day from Baseline Visit
 
000
 
030
 
060
 
090
-
334
 
365
 
395
-
699
 
730
 
735
 
Treatment
14
 
 
 
 
 
 
 
 
 
Dispense Investigational Product
1
 
(taken twice daily
2
)
 
 
X
 
X
 
X
 
X
3
 
X
3
 
X
3
 
 
 
Drug Accountability Review
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
Bevacizumab Injection
 
X
 
X
 
X
 
X
3
 
X
3
 
X
3
 
 
 
General Assessments
14
 
 
 
 
 
 
 
 
 
Medical/Ophthalmic History
 
X
 
 
 
 
 
 
 
 
Vital Signs
 
X
 
 
 
 
 
 
 
 
Physical Examination
 
X
6
 
 
 
 
 
 
 
 
Thyroid Palpation
4
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
 
Review of Systems
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
 
Allergies Assessment
 
X
 
 
 
 
 
 
 
 
Concomitant 
Medications 
Assessment
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Adverse Event Assessment
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Ophthalmic Assessments
14
 
 
 
 
 
 
 
 
 
BCVA (ETDRS)
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Manifest Refraction
5
 
X
 
 
 
 
X
 
 
 
X
 
 
Slit Lamp Examination
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Dilated Fundus Examination
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
 
Intraocular Pressure (IOP)
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Color Fundus Photography (CFP)
 
X
6
 
 
 
 
X
 
 
X
 
 
Spectral Domain Optical 
Coherence Tomography (OCT)
 
X
6
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Microperimetry
 
X
6
 
 
 
X
7
 
X
 
X
7
 
X
 
 
Fluorescein Angiogram (FA)
 
X
6
 
 
 
 
X
 
 
X
 
 
Laboratory 
Assessments
8
, 14
 
 
 
 
 
 
 
 
 
Acute Care Panel
 
X
9
 
 
X
 
X
10
 
 
X
10
 
X
 
X
 
Hepatic Panel
 
X
9
 
 
X
 
X
10
 
 
X
10
 
X
 
X
 
Complete Blood Count (CBC)
 
X
9
 
 
 
 
 
 
 
X
 
Thyroid Function Test
11
 
X
9
 
 
X
 
X
10
 
 
X
10
 
X
 
 
Pregnancy Test (urine)
12
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
 
 
*
 
These visit numbers correspond with the protocol visit numbers. All follow
-
up visits will be conducted within a window 
of 

7 days of the target day
, with the exception of the safety follow
-
up visit at the BRC sites, which can only occur at 
least five days 
following IP cessation
.
 
1
 
At the time the study medication is dispensed, participants will be provided a pill diary
 
and an information sheet outlining 
instructions on taking study medication and concomitant medications. 
 
2
 
Participants will take an oral pi
ll two times a day, once in the morning and once in the evening, approximately 
 
12 hours apart. The exception to this will occur on the day of the baseline visit, in which participants will take only the 
evening pill. 
 
3
 
The decision to continue dispensing 
IP
 
or injecting bevacizumab is determined by the scenarios described in Section 
4.
5
.2.
 
4 
 
Abnormal findings during a thyroid palpation will be followed by a referral to an endocrinologist.
 
 
5
 
BCVA with manifest refractio
n must also be performed when scheduled and when there is a change in VA of 
 
>
10 ETDRS letters (
>
 
0.20 logMAR) as compared with relevant baseline.
 
6
 
These procedures may be completed under another NEI protocol if performed within 1
-
7 days prior to the base
line visit.
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
51
 
7
 
Microperimetry will be performed at baseline and at Months 3, 6, 12, 18 and 24.
 
8
 
All abnormal values or positive tests will be reported to the participant’s primary care physician, with the participant’s 
permission.
 
9
 
These procedures may be
 
completed under another NEI protocol if performed within 42 days prior to the baseline visit.
 
10
 
 
The acute care and hepatic panels and thyroid function testing are performed at baseline, Month 2 and every four months 
thereafter (Months 6, 10, 14, 18 and 
22), as well as the final visit at Month 24.
 
11
 
 
Participants with abnormal thyroid function test results will be referred to an endocrinologist.
 
12
 
For women of childbearing potential only and they must have a negative test within 24 hours prior to initia
tion of 
IP
. 
For the BRC sites, f
or women of childbearing potential only and they must have a negative
 
serum pregnancy
 
test within 
24 hours prior to initiation of 
IP
. 
After initiation of contraception, urine pregnancy tests will be conducted; however, a 
ser
um test will be performed anytime a urine test result creates doubt. 
See Appendix 1 for guidance on determining 
whether a female is considered to be of childbearing potential. Some women may require a follicle
-
stimulating hormone 
(FSH) test to determine ch
ildbearing potential. 
 
13
 
Applicable to the BRC sites only: This visit must be conducted
 
at least five days after the last study drug administration
.
 
Additional assessments may be performed if deemed necessary by the investigator.
 
14
 
Applicable to the BRC sites only: 
In the event that the
 
baseline
 
testing was not completed within 
one
 
day, subsequent 
clinic visits may be scheduled within 
14
 
days of the first visit to complete the scheduled evaluation
s and treatments. If 
the Month 12 or 
Month 24 visit was not completed within one day, subsequent visits may be scheduled within 7 days of 
the first visit. If the baseline visit, Month 12 visit or Month 24 visit are conducted over more than one day, BCVA, OCT 
and microperimetry testing must be
 
completed on the day of the injection.
 
 
 
 
MiCRVO
 
September 19, 2018
 
Version 
19.0
 
CONFIDENTIAL
 
Page 
52
 
A
PPENDIX 
3
:
 
L
IST OF 
D
EFINITIONS
 

 
Improvement
:
 
Visual acuity in the study eye of 
>
 
84
-
88 letters (20/20) OR OCT central 
subfield thickness < 300 microns.
 

 
Worsening
:
 
A decrease in visual acuity of 
≥15 or more letters in the study eye compared 
to baseline, AND an increase in OCT central subfield thickness 
≥
 
1
-
step log unit compared 
to bas
eline for at least two consecutive visits
.
 

 
New Steady State:
 
Improvement and worsening criteria not met and central subfield 
thickness
 
remains 
≥
 
300 microns
 
on OCT but thickness is stable and has not changed 
 
> 25 microns over the last three consecutive injections.
 

 
No improvement
:
 
Improvement and worsening criteria are not met and visual acuity failed 
to increase by 
≥ 
10 letters in the study eye compared to b
aseline AND OCT central subfield 
thickness
 
failed to 
decrease by 
≥ 1
-
step log unit compared to baseline.
 